US Pat. No. 10,363,301

STABILIZED INFLUENZA HEMAGGLUTININ STEM REGION TRIMERS AND USES THEREOF

The United States of Amer...

1. A nanoparticle comprising a protein construct that comprises an HA protein domain and a linker sequence, wherein the HA protein domain comprises the sequence of an influenza hemagglutinin (HA) protein that lacks at least 95% of the head region amino acid sequence, and in place of the missing sequence comprises a linker sequence, wherein the linker sequence is less than 10 amino acids in length; and,wherein the HA protein comprises at least one alteration selected from the group consisting of:
a. deletion of the amino acid region corresponding to amino acids N403-W435 of SEQ ID NO:8; and,
b. substitution of at least one amino acid residue in a pair of amino acid residues, wherein the amino acid residues correspond to K1 and E53 of SEQ ID NO:149; and, wherein the strength of the bond between the amino acid pair in the folded, altered protein is greater than the strength of the bond between the amino acid pair in the folded, wild-type protein.
US Pat. No. 10,363,302

INFLUENZA NUCLEIC ACID MOLECULES AND VACCINES THEREFROM

THE TRUSTEES OF THE UNIVE...

1. An isolated nucleic acid molecule comprising one or more nucleic acid molecules selected from the group consisting of:i) a nucleic acid molecule encoding the amino acid sequence of SEQ ID NO:2,
ii) a nucleic acid molecule encoding the amino acid sequence of SEQ ID NO:4,
iii) a nucleic acid molecule encoding the amino acid sequence of SEQ ID NO:7,
iv) a nucleic acid molecule encoding the amino acid sequence of SEQ ID NO:10, and
v) a nucleic acid molecule encoding the amino acid sequence of SEQ ID NO:12.
US Pat. No. 10,364,326

POROUS/NANOPOROUS PHT

International Business Ma...

1. A polymeric material comprising a plurality of hexahydrotriazine units, hemiaminal units, or both bonded together by a first linkage and a second linkage, wherein the first linkage is thermally stable and resistant to bases and the second linkage is thermally degradable and degradable by a base.
US Pat. No. 10,363,304

PURIFICATION OF HERPES VIRUS

SANOFI PASTEUR BIOLOGICS,...

1. A composition comprising Herpes Simplex Virus (HSV) particles in a liquid stabilization buffer, wherein the liquid stabilization buffer comprises glutamate, 1-20 mM histidine and optionally glutamine, a salt, and a sugar, and wherein other than histidine and optionally glutamine, the liquid stabilization buffer does not contain any other amino acids.
US Pat. No. 10,364,328

METHOD FOR PRETREATING LIGNOCELLULOSE BY USING ACID-BASE MIXTURE CATALYST

Korea University Research...

1. A method for pretreating lignocellulosic biomass comprising:reacting an aqueous acid-base mixture catalyst having a pH value of 1 to 4 with lignocellulosic biomass at 100 to 200° C. for 60 seconds to 2 hours;
wherein the acid is selected from the group consisting of sulfuric acid, maleic acid, hydrochloric acid, nitric acid, phosphoric acid, carbonic acid, formic acid, acetic acid, hydrofluoric acid, oxalic acid, citric acid, and mixtures of two or more thereof;
wherein the base is selected from the group consisting of sodium hydroxide, potassium hydroxide, calcium hydroxide, barium hydroxide, ammonium hydroxide, calcium carbonate, potassium carbonate, ammonia, and mixtures of two or more thereof; and
wherein said acid-base mixture catalyst has an acid:base molar ratio of 4:1, and has a total concentration of 0.05 M to 0.5 M.
US Pat. No. 10,364,329

THERMOPLASTIC RESIN COMPOSITION AND MOLDED ARTICLE INCLUDING THE SAME

LG CHEM, LTD., Seoul (KR...

1. A thermoplastic resin composition, comprising: 100 parts by weight of a base resin comprising (a) an aromatic vinyl compound-conjugated diene-based compound-vinyl cyan compound copolymer and (b) an aromatic vinyl compound-vinyl cyan compound copolymer comprising ?-methylstyrene; and (c) between 0.5 parts by weight and 5 parts by weight of a polyethylene oxide-polypropylene oxide triblock copolymer,wherein (a) the aromatic vinyl compound-conjugated diene-based compound-vinyl cyan compound copolymer is comprised in an amount of 10% by weight to 50% by weight with respect to the base resin,
wherein (b) the aromatic vinyl compound-vinyl cyan compound copolymer is comprised in an amount of 50% by weight to 90% by weight with respect to the base resin, and
wherein a number average molecular weight (Mn) of the polypropylene oxide is 1,000 to 1,750 g/mol.
US Pat. No. 10,362,794

THRAUSTOCHYTRIDS, FATTY ACID COMPOSITIONS, AND METHODS OF MAKING AND USES THEREOF

DSM IP Assets B.V., TE H...

1. A microbial oil comprising a triglyceride fraction of from 75% to 95% by weight, wherein the docosahexaenoic acid content of the triglyceride fraction is from 40% to 80% by weight, wherein the arachidonic acid content of the triglyceride fraction is from 0.1% by weight to 1.5% by weight, wherein said microbial oil further comprising an effective amount of at least one added antioxidant to provide oxidative stability.
US Pat. No. 10,363,306

CYTOKINES AND NEUROANTIGENS FOR TREATMENT OF IMMUNE DISORDERS

East Carolina University,...

1. A method of treating multiple sclerosis in a subject comprising administering to the subject an effective amount of a composition comprising:(a) at least one fusion protein comprising, from N-terminal to C-terminal, (i) a cytokine, wherein the cytokine is interferon-? (IFN-?); (ii) optionally an enterokinase linking moiety, wherein the enterokinase linking moiety is (1) an amino acid sequence of SEQ ID NO:1, (2) an amino acid sequence having at least 80% identity or homology with the amino acid sequence of SEQ ID NO:1, (3) an amino acid sequence encoded by a nucleic acid sequence encoding an enterokinase recognition site, or (4) an amino acid sequence encoded by a nucleic acid sequence that hybridizes with the complement of the nucleic acid sequence of (3) under stringent conditions as represented by hybridization conditions of 0.5M NaHPO4, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65° C. and wash conditions of 0.1×SSC/0.1% SDS at 68° C.; and (iii) an autoimmune antigen, or portion thereof, wherein the autoimmune antigen is myelin basic protein (MBP);
(b) a cytokine, wherein the cytokine is IFN-?; and
(c) a pharmaceutically acceptable carrier, excipient or diluent.
US Pat. No. 10,364,330

PROCESS TO PREPARE BIAXIALLY ORIENTED FILM

DSM IP ASSETS B.V., Heer...

1. A process for preparing a biaxially oriented film, comprising the following steps:a) forming a polymer melt by melting a polymer composition comprising at least 50 wt % with respect to the total amount of the composition of a copolyamide comprising:
(i) at least 75 wt % monomeric units derived from caprolactam, and further monomeric units derived from diamines X and/or diacids Y and/or aminoacids Z in a summed amount of between 0.2 to 10 wt %; or
(ii) at least 75 wt % monomeric units derived from hexamethylene diamine and adipic acid, and further monomeric units derived from diamines X, diacids Y and/or aminoacids Z in a summed amount of between 0.2 to 10 wt %; wherein
at least one of the further monomeric units derived from diamines X and/or diacids Y and/or amino acids Z is cyclic;
b) casting the polymer melt through a planar die to form a film of at least one layer and subsequently quenching the film to a temperature of below Tg of the copolyamide;
c) stretching the film obtained after quenching in a direction parallel to a machine direction (MD-stretching) with a factor of at least 2 at a temperature of at least Tg of the copolyamide to obtain a MD-stretched film;
d) stretching the MD-stretched film obtained after MD stretching in a direction transverse to the machine direction (TD-stretching) with a factor of at least 2 at a temperature of at least Tg+10° C. of the copolyamide to obtain a biaxially stretched film;
e) cooling the obtained biaxially stretched film after TD-stretching at a temperature of at least 10° C. lower than the temperature of the TD-stretching in step d); and
f) heat setting the biaxially stretched film obtained after cooling, at a temperature of between Tm?70° C. and Tm of the copolyamide to obtain a biaxially oriented film; wherein
the temperatures Tg and Tm of the copolyamide are determined as described by ASTM D3418-03.
US Pat. No. 10,363,307

METHODS OF TREATING PSORIATIC ARTHRITIS USING IL-17 ANTAGONISTS

Novartis AG, Basel (CH)

1. A method of treating Psoriatic Arthritis (PsA), comprising:a) subcutaneously administering to a patient having PsA five doses of about 150 mg-about 300 mg of an IL-17 antibody, each of the five doses being delivered weekly; and
b) thereafter, subcutaneously administering to the patient a dose of about 150 mg-about 300 mg of the IL-17 antibody every month, wherein the IL-17 antibody comprises:
i) an immunoglobulin VH domain comprising the amino acid sequence set forth as SEQ ID NO:8 and an immunoglobulin VL domain comprising the amino acid sequence set forth as SEQ ID NO:10;
ii) an immunoglobulin VH domain comprising the hypervariable regions comprising the amino acid sequences set forth as SEQ ID NOs:1-3, respectively, and an immunoglobulin VL domain comprising the hypervariable regions comprising the amino acid sequences set forth as SEQ ID NOs:4-6, respectively; or
iii) an immunoglobulin VH domain comprising the hypervariable regions comprising the amino acid sequences set forth as SEQ ID NOs:11-13, respectively, and an immunoglobulin VL domain comprising the hypervariable regions comprising the amino acid sequences set forth as SEQ ID NOs:4-6, respectively.
US Pat. No. 10,362,796

METHOD FOR REDUCING THE CONTENT OF PATHOGENIC ORGANISMS PRESENT IN FOOD MATERIALS

1. A fermented food product produced by a method comprising:(i) mixing a food material with (a) a starter culture and (b) at least one adjunct culture comprising Pediococcus acidilactici that produces a bacteriocin;
(ii) fermenting the food material at a sub-optimal temperature for growth of the Pediococcus acidilactici of 30° C. or below; and
(iii) ripening the food material;
wherein during fermentation the acidification caused by the Pediococcus acidilactici is about 0.5 pH unit or less, and wherein growth of Listeria monocytogenes during fermentation and/or ripening is suppressed, and
wherein the pH of the fermented food product is at most 0.5 pH units lower than that of a fermented food product produced by the same method except without the Pediococcus acidilactici adjunct culture.
US Pat. No. 10,363,309

TARGETED NANOPARTICLE CONJUGATES

CASE WESTERN RESERVE UNIV...

1. A composition for treating a disorder in a subject, the composition comprising:a polyethylene glycolylated (PEGylated) nanoparticle;
at least one hydrophobic therapeutic agent non-covalently coupled to the surface of the nanoparticle, wherein the at least one hydrophobic therapeutic agent has an amino or amine functionality for attachment to the surface of the nanoparticle; and
at least one targeting moiety coupled to polyethylene glycol of the nanoparticle for targeting the composition to a cell associated with the disorder, wherein the at least one therapeutic agent is released from the nanoparticle and differentially up taken by the cell upon targeting with reduced nanoparticle accumulation in the cell.
US Pat. No. 10,363,310

PROTON INDUCED BORON CAPTURE THERAPY

1. A method of treating a biological tissue using a proton beam, comprising steps of:introducing a reactant into a biological tissue, the reactant comprising a composite and being distributed in the biological tissue; and
irradiating the biological tissue with the proton beam,
wherein the composite comprises 10B and 11B, the composite reacts with at least one proton from the proton beam to release at least one ? particle or ? rays, and the ? particle or the ? rays reacts with the biological tissue.
US Pat. No. 10,363,311

ENGINEERED PRIMATE CYSTINE/CYSTEINE DEGRADING ENZYMES AS ANTINEOGENIC AGENTS

BOARD OF REGENTS, THE UNI...

1. An isolated, modified primate cystathionine-?-lyase (CGL) enzyme having at least one substitution relative to a native primate CGL amino acid sequence (see SEQ ID NOs: 1 and 7-10), said at least one substitution including a threonine at position 59 of the native primate CGL sequence.
US Pat. No. 10,362,800

POWDEROUS VITAMIN E FORMULATIONS

DSM IP ASSETS B.V., Heer...

1. A powderous formulation comprising:(i) at least 40 wt-%, based on the total weight of the powderous formulation, of a porous particulate carrier material,
(ii) at least 50 wt-%, based on the total weight of the powderous formulation, of vitamin E coated onto the porous particulate carrier material, and
(iii) 0.5 wt-%-8 wt-%, based on the total weight of the powderous formulation, of at least one auxiliary compound selected from the group consisting of aluminium ammonium sulphate, aluminium potassium sulfate, ammonium acetate, ammonium bisulphite, ammonium carbonate, ammonium chloride, ammonium dihydrogen phosphate ammonium hydrogen carbonate, bentonite, montmorillonite, calcium aluminates, calcium carbonate, calcium silicate, synthetic calcium sulphate di-hydrate, calcium sulfate, kaolinitic clays, diatomaceous earth, perlite, potassium bisulphite, potassium hydrogen carbonate, potassium sulphate, potassium carbonate, sepiolitic clays, silicic acid, synthetic sodium aluminosilicate, sodium aluminosulfate, sodium bisulphate, sodium carbonate, sodium chloride, sodium hydrogen carbonate, sodium sulphate, vermiculite, calcium carbonate, magnesium carbonate, calcareous marine algae, magnesium oxide, magnesium sulphate, dicalcium phosphate, tri-calcium phosphate, dicalcium phosphate, defluorinated rock-phosphate, monocalcium phosphate, calcium-magnesium phosphate, mono-ammonium phosphate, magnesium phosphate, sodium-calcium-magnesium phosphate, mono-sodium phosphate, glycerol, propylene glycol, glyceryl triacetate, sorbitol, polydextrose, lactic acid and urea, wherein
the at least one auxiliary compound has an average particle size (d 0.5) of 54-100 ?m in the formulation, and wherein
the powderous formulation has a minimum ignition energy (MIE) value according to EN 13821:2002 of 10 to 1000 mJ.
US Pat. No. 10,363,312

PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM

AXSOME THERAPEUTICS, INC....

1. A method of treating migraine comprising: orally administering a solid dosage form once daily to a human being suffering from a migraine, wherein the solid dosage form comprises: 1) a complex of meloxicam and a sulfobutyl ether ?-cyclodextrin (SBE?CD), and 2) a bicarbonate, wherein orally administering the solid dosage form to the human being results in a Tmax of meloxicam that is shorter than a Tmax of a reference solid dosage form that: 1) contains the same amount of meloxicam, 2) does not contain an SBE?CD, and 3) does not contain a bicarbonate, wherein the solid dosage form has been shown to have a median Tmax of meloxicam that is less than 2 hours in human subjects.
US Pat. No. 10,362,801

WRAPPING PAPER HAVING TRANSPARENT REGIONS

delfortgroup AG, Traun (...

1. A wrapping paper for smoking articles, which contains pulp fibers and at least one acid-soluble filler material, wherein the content of acid-soluble filler material is at least 10% by weight with respect to the total mass of the wrapping paper, wherein the wrapping paper has regions of lower transparency and regions of higher transparency, wherein the fraction of the mass per unit area of said acid-soluble filler material is at least 10% lower in the regions of higher transparency than in the regions of lower transparency, and wherein for the transparency in the regions of higher transparency, at least one of the following criteria is met:the transparency measured in accordance with DIN 53147:1993-01 in the regions of higher transparency is at least 20% higher than the transparency measured in accordance with DIN 5314:1993-01 in the regions of lower transparency, or
the transparency in the regions of higher transparency is so much higher than in the regions of lower transparency that, when the wrapping paper is wrapped around a tobacco rod with an American Blend tobacco blend, a diameter of 7 mm to 8 mm and a filling density of 0.1 g/cm3 to 0.3 g/cm3, a pattern of lighter and darker sections is obtained which is perceptible to the naked eye, wherein the darker sections correspond to the regions of higher transparency and the lighter sections correspond to the regions of lower transparency.
US Pat. No. 10,363,315

COMPOSITION FOR TREATMENT OF A DETACHED RETINA AND METHOD OF PRODUCTION THEREOF

University of Liverpool, ...

1. A composition for medical use in treatment of a detached retina, the composition comprising an oil and an additive capable of increasing the extensional viscosity of the oil, wherein the oil has a viscosity of less than 5,000 mPas and is at least one selected from the group consisting of: a silicone oil, a perfluorocarbon oil, and a semi-fluorinated alkane oil, wherein the additive is a silicone oil having a viscosity of 2,500,000 mPas, and is present in the range of 0.05%-20% w/w of the composition, the composition effective to prevent formation of an emulsion with protein, for the medical use of the composition in the treatment of the detached retina.
US Pat. No. 10,367,157

ENERGY SENSITIZATION OF ACCEPTORS AND DONORS IN ORGANIC PHOTOVOLTAICS

University of Southern Ca...

1. An organic photosensitive optoelectronic device comprising:two electrodes in superposed relation;
a mixed organic acceptor layer and an organic donor layer located between the two electrodes, wherein the mixed organic acceptor layer comprises a mixture of an acceptor material and at least one acceptor sensitizer, wherein the acceptor material is chosen from fullerenes and fullerene derivatives, and wherein the acceptor material and the at least one acceptor sensitizer are chosen to satisfy the following conditions:
the at least one acceptor sensitizer has a lowest singlet excited state energy (ES-ASens) greater than or equal to a lowest singlet excited state energy (ES-A) of the acceptor material;
the at least one acceptor sensitizer has a lowest triplet excited state energy (ET-Asens) greater than or equal to a lowest triplet excited state energy (ET-A) of the acceptor material;
the at least one acceptor sensitizer has a reduction potential lower than or equal to a reduction potential of the acceptor material; and
if the at least one acceptor sensitizer and the acceptor material form a charge transfer (CT) state having a CT state energy, the CT state energy is greater than or equal to the lowest triplet excited state energy (ET-A) of the acceptor material.
US Pat. No. 10,364,344

THERMOPLASTIC RESIN COMPOSITION EXHIBITING SUPERIOR MATTE AND GLOSS, AND MOLDED ARTICLE MANUFACTURED FROM THE SAME

LG CHEM, LTD., Seoul (KR...

1. A thermoplastic resin composition, comprising:10 to 59% by weight of an acrylic graft copolymer resin (a) having a graft efficiency of 50 to 95%, the resin (a) comprising 10 to 60% by weight of an acrylic rubber, 30 to 60% by weight of an aromatic vinyl compound, and 10 to 30% by weight of a vinyl cyan compound;
1 to 20% by weight of an acrylic graft copolymer resin (b) having a graft efficiency of 10-20%, the resin (b) comprising 60 to 95% by weight of an acrylic rubber, 1 to 30% by weight of an aromatic vinyl compound, and 1 to 20% by weight of a vinyl cyan compound; and
21 to 89% by weight of an aromatic vinyl compound-vinyl cyan compound copolymer resin (c),
wherein a weight ratio of (a):(b) is 1:1 to 10:1.
US Pat. No. 10,363,321

NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF

Factor Bioscience Inc., ...

1. An in vivo method for treating cancer in a subject comprising:administering to the subject by intratumoral injection a non-viral, cell-free composition comprising a synthetic messenger RNA (mRNA) encoding a gene-editing protein capable of creating a single-strand or double-strand break in an immune checkpoint molecule gene, and
causing a single-strand or double-strand break in the DNA of a tumor cell, the single-strand or double-strand break being localized to an immune checkpoint molecule gene in the tumor cell in the subject, resulting in the stimulation or enhancement of an immune response in the subject;thereby treating cancer in the subject.
US Pat. No. 10,364,348

THERMOPLASTIC RESIN COMPOSITION AND MOLDED ARTICLE COMPRISING THE SAME

Lotte Advanced Materials ...

1. A thermoplastic resin composition comprising:about 100 parts by weight of a base resin comprising about 65 wt % to about 80 wt % of a polycarbonate (PC) resin and about 20 wt % to about 35 wt % of a polyester resin;
about 20 parts by weight to about 40 parts by weight of inorganic fillers; and
about 3 parts by weight to about 15 parts by weight of an aromatic (meth)acrylate polymer;
wherein the aromatic (meth)acrylate polymer is a copolymer of a monomer mixture comprising a vinyl cyanide monomer, an aromatic vinyl monomer and an aromatic (meth)acrylate.
US Pat. No. 10,364,351

PROCESS FOR THE MANUFACTURE OF TANKS HAVING HIGH BARRIER PROPERTIES TOWARD FLUIDS

RHODIA OPERATIONS, Auber...

1. A process for making a tank having high barrier properties toward fluids, comprising:assembling one or more components made by injection molding of a polyamide composition, optionally with one or more other components, in order to obtain the tank; said polyamide composition comprising a polyamide and from 5% to 40% by weight of an impact strength modifier, wherein the impact strength modifier has a mean particle size of between 0.1 and 1 ?m and is defined as having an ASTM D-638 tensile modulus of less than about 500 MPa;
said polyamide composition further comprising a novolac resin; and
said polyamide composition exhibiting the following characteristics:
a melt viscosity of between 50 and 700 Pa·s, measured according to the standard ISO 11443, at a shear gradient of 1000 s?1 and a temperature equal to the melting point of the polyamide +35° C.; and
a permeability to SP95 E10 alcohol-blend gasoline of less than or equal to 10 g·mm/m2·day, as measured at a temperature of 40° C. and a relative humidity of 20%,
wherein:
the polyamide composition is devoid of cyclodextrin and silica;
the polyamide composition is substantially free of plasticizers;
the impact strength modifier comprises at least 20% by weight, based on the total weight of the impact strength modifier, of reactive impact strength modifier that comprises functional groups that are reactive with the polyamide, and/or
the polyamide composition further comprises at least 10% by weight, based on the total weight of the impact strength modifier, of a compatibilizing agent that comprises functional groups that are reactive with the polyamide.
US Pat. No. 10,364,363

RADIATION CURABLE BINDER DISPERSION

Hewlett-Packard Developme...

1. A radiation curable binder dispersion, comprising:water; and
a radiation curable polyurethane dispersed in the water, the radiation curable polyurethane having been formed from:
a polyisocyanate;
an acrylate or methacrylate, the acrylate or methacrylate having at least two hydroxyl functional groups and having an acrylate functional group or a methacrylate functional group;
an other acrylate or methacrylate, the other acrylate or methacrylate having one hydroxyl functional group or one amino functional group; and one of:
i) a homopolymer or copolymer of poly(ethylene glycol) having one or two hydroxyl functional groups or one or two amino functional groups at one end of its chain; or
ii) a combination of i and a compound including a carboxylic functional group.
US Pat. No. 10,363,341

COMPOSITE TISSUE-ENGINEERED INTERVERTEBRAL DISC WITH SELF-ASSEMBLED ANNULAR ALIGNMENT

Cornell University, Itha...

1. A method of fabricating a tissue-engineered intervertebral disc (IVD) suitable for total disc replacement in a mammal, said method comprising:providing a first gel comprising a first population of living cells that secrete a hydrophilic protein;
forming the first gel into a predetermined shape and size;
providing a second different gel comprising a second different population of living cells and collagen;
contacting the formed first gel with the second gel at a region that extends circumferentially around the first gel; and
storing the first and second gels under conditions effective for the collagen in the second gel to align circumferentially around the first gel by self-assembly of collagen due to cell-mediated gel contraction in the second gel, wherein the first gel forms a nucleus pulposus structure and the second gel forms an annulus fibrosus structure surrounding and in contact with the nucleus pulposus structure, thereby fabricating a tissue-engineered IVD suitable for total disc replacement in a mammal.
US Pat. No. 10,364,369

LOW DUST ADDITIVES COMPRISING EMULSIFIED POWDER FOR JOINT COMPOUNDS AND JOINT COMPOUNDS THEREOF

Henry Company, LLC, El S...

1. A low-dust joint compound composition comprising a dust reduction additive emulsified powder, wherein said dust reduction additive emulsified powder is made from an emulsion comprising a colloidally-protected-waxed-based (CPWB) microstructure comprising:(A) a wax core,
wherein said wax core comprises a micro-crystalline wax component, a non-micro-crystalline wax component, or a combination thereof,
wherein said micro-crystalline wax component comprises at least one linear alkane wax defined by the general formula CnH2n+2, where n ranges from 13-80,
wherein said non-micro-crystalline wax component comprises at least one wax selected from the group consisting of animal-based wax, plant-based wax, mineral wax, synthetic wax, a wax containing organic acids and/or esters, anhydrides, an emulsifier containing a mixture of organic acids and/or esters, and combinations thereof; and
(B) a polymeric shell,
wherein said polymeric shell comprises at least one polymer selected from the group consisting of polyvinyl alcohol, polyvinyl alcohol copolymers, polyvinyl alcohol terpolymers, polyvinyl acetate, polyvinyl acetate copolymers, polyvinyl acetate terpolymers, cellulose ethers, polyethylene oxide, polyethyleneimines, polyvinylpyrrolidone, polyvinylpyrrolidone copolymers, polyethylene glycol, polyacrylamides polyethylene glycol, polyacrylamides and poly(N-iso-propylamides), pullulan, sodium alginate, gelatin, starches, and combinations thereof.
US Pat. No. 10,364,379

OXAZOLINE-CONTAINING AQUEOUS POLYMER DISPERSIONS FOR COMPOSITE FILM LAMINATION

BASF SE, Ludwigshafen (D...

1. A laminating adhesive, comprising an aqueous polymer dispersion comprising a polymer having a glass transition temperature of less than ?10° C., wherein the polymer comprises, in polymerized form:ethylenically unsaturated, radically polymerizable monomers;
at least one monomer having at least one acid group, in an amount of at least 0.1 part by weight, based on 100 parts by weight of all polymerizable monomers; and
at least one monomer having at least one oxazoline group.
US Pat. No. 10,364,380

ADHESIVE COMPOSITION FOR OPTICAL USE, METHOD FOR PREPARING ADHESIVE COMPOSITION FOR OPTICAL USE, AND ADHESIVE FILM FOR OPTICAL USE

LG Chem, Ltd., (KR)

1. An adhesive composition for optical use, comprising:an isobutylene-isoprene rubber having an acrylic acid ester-based functional group in a main chain thereof;
a photoinitiator; and
a tackifier,
wherein the acrylic acid ester-based functional group is grafted to an isoprene unit of the isobutylene-isoprene rubber through a urethane bond.
US Pat. No. 10,364,381

RELEASE FILM

MITSUBISHI CHEMICAL CORPO...

1. A release film comprising a polyester film and a coating layer formed on at least one surface of the polyester film, which coating layer is formed by coating a coating solution comprising an addition curing silicone compound, a Gemini surfactant, and a platinum group metal catalyst and curing thereof.
US Pat. No. 10,364,382

CURABLE POLYSILOXANE COMPOSITIONS AND PRESSURE SENSITIVE ADHESIVES MADE THEREFROM

3M Innovative Properties ...

1. A curable composition comprising:at least one polydiorganosiloxane, comprising at least two hydroxysilyl moieties; wherein the at least one polydiorganosiloxane, comprising at least two hydroxysilyl moieties comprises the following general formula:
(OH)p—Si(R?)3-p-[G-Si(R?)2]t—O—[(R?)2SiO]q[Si(R?)2G]t—Si(R?)3-p—(OH)p  (I)
wherein each p is independently an integer of 1, 2, or 3; each G is independently a divalent linking group; each R? is independently selected from alkyl, alkenyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, and combinations thereof; q is an integer of 0 to 150,000; and each t is independently an integer of 0 or 1
at least one hydroxyl-functional polyorganosiloxane resin; and
at least one photoactivatable composition that, upon exposure to radiation, generates at least one base selected from amidines, guanidines, phosphazenes, proazaphosphatranes, and combinations thereof, wherein the curable composition cures upon exposure to radiation of the appropriate wavelength to activate the photoactivatable composition and upon curing is a pressure sensitive adhesive.
US Pat. No. 10,364,383

ABRASIVE PARTICLES HAVING COMPLEX SHAPES AND METHODS OF FORMING SAME

1. A shaped abrasive particle comprising:a generally prismatic body having a length, width, and thickness;
wherein the length is greater than the width and the length is greater than the thickness;
wherein the generally prismatic body with a first end face and a second end face have a polygonal shape; and
wherein the generally prismatic body comprises an odd number of major surfaces.
US Pat. No. 10,367,200

POSITIVE ELECTRODE ACTIVE MATERIAL SLURRY INCLUDING TWO TYPES OF BINDERS AND POSITIVE ELECTRODE PREPARED THEREFROM

LG Chem, Ltd., (KR)

1. A positive electrode active material slurry comprising:a positive electrode active material;
a first binder;
a second binder; and
an organic solvent,
wherein the first binder is a fluorine-based binder,
the second binder is a butadiene rubber-based binder, and
the first binder and the second binder have a weight ratio of 9:1 to 7:3,
wherein the positive electrode active material is included in 50% by weight to 65% by weight with respect to total solid content of the positive electrode active material slurry,
wherein the positive electrode active material is a lithium iron phosphate-based positive electrode active material represented by the following Chemical Formula 1:
Li1+aFe1-xMx(PO4-b)Xb  [Chemical Formula 1]
wherein, in Chemical Formula 1,
M is Al, Mg, Ni, Co, Mn, Ti, Ga, V, Nb, Zr, Ce, In, Zn, Y or a combination thereof,
X is F, S, N or a combination thereof,
a is ?0.5?a?0.5,
b is 0?b?0.1, and
x is 0?x?0.5.
US Pat. No. 10,362,850

DYE-FREE NAIL VARNISH COMPOSITIONS AND METHODS THEREOF

1. A nail varnishing system, comprising:a nail varnish composition including a plurality of photonic particles, a block copolymer, or both a plurality of photonic particles and a block copolymer, wherein the block copolymer is selected from a poly(styrene-b-isoprene) diblock copolymer, poly(styrenesulfonate-methylbutylene), and polystyrene-poly (2-vinylpyridine); and
a stamp including a pattern of repeating nanostructures, wherein the stamp is configured to transfer the pattern of repeating nanostructures to a coating of the nail varnish composition to provide a pattern of repeating photonic nanostructures on the coating of the nail varnish composition.
US Pat. No. 10,365,411

HARDCOAT FILM, POLARIZING PLATE, LIQUID CRYSTAL DISPLAY, AND METHOD FOR MANUFACTURING HARDCOAT FILM

FUJIFILM Corporation, To...

1. A hardcoat film comprising:a support; and
a hardcoat layer disposed on at least one surface of the support,
wherein the support contains a resin as a main component;
wherein a film thickness of the hardcoat layer exceeds 20 ?m;
wherein the hardcoat layer contains at least a structure derived from a), b), c), d) and g);
wherein:
a) compound which has one alicyclic epoxy group and one ethylenically unsaturated double bond group in a molecule and has a molecular weight equal to or less than 300;
b) compound which has 3 or more ethylenically unsaturated double bond groups in a molecule;
c) radical polymerization initiator;
d) cationic polymerization initiator; and
g) antifoulant which has a plurality of polymerizable unsaturated groups in one molecule;
wherein, on condition that a total solid content of the hardcoat layer is regarded as being 100% by mass, the hardcoat layer contains the structure derived from a) in an amount of 15% to 70% by mass, the structure derived from b) in an amount of 25% to 80% by mass, c) in an amount of 0.1% to 10% by mass, d) in an amount of 0.1% to 10% by mass, and the structure derived from g) in an amount of 1% to 20% by mass;
wherein the hardcoat layer is formed by curing a composition for forming a hardcoat layer containing at least a), b), c), d) and g);
wherein, on condition that a total solid content of the composition for forming a hardcoat layer is regarded as being 100% by mass, the composition contains a) in an amount of 15% to 70% by mass, b) in an amount of 25% to 80% by mass, c) in an amount of 0.1% to 10% by mass, d) in an amount of 0.1% to 10% by mass, and g) in an amount of 1% to 20% by mass;
wherein the pencil hardness of the hardcoat film is 6H or more;
wherein a) compound which has one alicyclic epoxy group and one ethylenically unsaturated double bond group in a molecule and has a molecular weight equal to or less than 300 is epoxycyclohexylmethyl (meth)acrylate;
wherein g) antifoulant which has a plurality of polymerizable unsaturated groups in one molecule contains a fluorine-containing compound;
wherein the fluorine-containing compound has a perfluoropolyether group and a plurality of polymerizable unsaturated groups in one molecule; and
wherein the fluorine-containing compound is compatible and forms covalent bonds with a) and b), and the structure derived from g) is distributed within the hardcoat layer in a film thickness direction in such a state that a percentage of an amount of fluorine in the vicinity of the surface of the hardcoat layer, to an amount of fluorine in the entirety of the hardcoat layer, is higher than 51%.
US Pat. No. 10,367,204

ALUMINUM ALLOY FOIL FOR ELECTRODE CURRENT COLLECTORS AND MANUFACTURING METHOD THEREOF

UACJ Corporation, Tokyo ...

1. An aluminum alloy foil for an electrode current collector, comprising 0.03 to 0.1 mass % (hereinafter, “mass %” is simply referred to as “%”) of Fe, 0.01 to 0.1% of Si, and 0.0001 to 0.01% of Cu, with the rest being Al and unavoidable impurities, wherein the aluminum alloy foil after final cold rolling has a tensile strength of 180 MPa or higher, a 0.2% yield strength of 160 MPa or higher, and an electrical conductivity of 60% IACS or higher; and the aluminum alloy foil has a tensile strength of 170 MPa or higher and a 0.2% yield strength of 150 MPa or higher even after the aluminum alloy foil is subjected to heat treatment at any of 120° C. for 24 hours, 140° C. for 3 hours, and 160° C. for 15 minutes.
US Pat. No. 10,364,404

MARINE ENGINE LUBRICATION

INFINEUM INTERNATIONAL LI...

1. A trunk piston marine engine lubricating oil composition for improving asphaltene handling in use thereof, in operation of such engine when fuelled by a heavy fuel oil, which composition comprises, or is made by admixing, an oil of lubricating viscosity and, in respective minor amounts:(A) an overbased metal hydrocarbyl-substituted hydroxybenzoate detergent system, and
(B) a hydrocarbyl-substituted succinic acid anhydride, made from halogen- or radical-assisted functionalization processes, where the ratio of succinic anhydride groups per substituted hydrocarbyl moiety is in the range of 1.4 to 4.
US Pat. No. 10,367,221

DISTRIBUTED ENERGY STORAGE SYSTEM

The Curators of the Unive...

1. An energy storage system, comprising:a first tank configured for storing an anolyte;
a second tank configured for storing a catholyte;
a reaction cell configured for distribution throughout a transport system and for supplying electrical current to an electrical load of the transport system, said reaction cell being elongate and comprising an anode electrode in fluid communication with the first tank and a cathode electrode in fluid communication with the second tank, said reaction cell further comprising a membrane configured to form an interface between the anode electrode and cathode electrode;
a first pump configured for pumping the anolyte from the first tank through the anode electrode of the reaction cell via a first input supply tube; and
a second pump configured for pumping the catholyte from the second tank through the cathode electrode of the reaction cell via a second input supply tube; and
wherein a length of the reaction cell is substantially greater than a width thereof and the length of the reaction cell is greater than at least one of a width and a length of the transport system, and wherein the membrane has a length substantially equal to the length of the reaction cell such that surface area of the membrane is maximized relative to volume of the reaction cell.
US Pat. No. 10,364,405

TRANSPARENT SOLID DETERGENT

AJINOMOTO CO., INC., Tok...

1. A transparent solid detergent, comprising:(A) at least one N-acyl glutamic acid salt, wherein said at least one N-acyl glutamic acid salt comprises N-lauroylglutamic acid salt, myristoylglutamic acid salt, and cocoylglutamic acid salt;
(B) at least one acylglycine salt, wherein said at least one acylglycine salt comprises cocoylglycine salt;
(C) at least one polyvalent alcohol, wherein said at least one polyvalent alcohol comprises glycerol; and
(D) at least one lower alcohol,
wherein
said (A) at least one N-acyl glutamic acid salt is present in an amount of 35 to 45 parts by weight per 1 part by weight of said (B) at least one acylglycine salt;
said (C) at least one polyvalent alcohol is present in an amount of 11 to 24 parts by weight, per 1 part by weight of said (B) at least one acylglycine salt, and said (D) at least one lower alcohol is present in an amount of 2.5 to 30 parts by weight per 1 part of said (B) at least one acylglycine salt.
US Pat. No. 10,364,407

KIT AND METHOD FOR CLEANING AND DISINFECTING MEDICAL INSTRUMENTS AND APPLIANCES

1. A kit for machine cleaning and/or disinfecting of medical and/or surgical instruments and/or appliances, characterized in that it comprises:a) a first component which comprises 15 to 30 wt % of alkanolamine, wherein the alkanolamine comprises mono-, di-, and/or triethanolamine, and 10 to 30 wt % of complexing agent; and
b) a second component which comprises at least one enzyme.
US Pat. No. 10,364,409

SOLIDIFICATION MATRIX COMPRISING A CARBOXYLIC ACID TERPOLYMER

Ecolab USA Inc., Saint P...

1. A solid detergent composition comprising:between about 0.1 wt-% and about 20 wt-% of a terpolymer (A), said terpolymer (A) comprising in copolymerized form from about 75% by weight of acrylic acid, of about 20% by weight of 2-acrylamido-2-methylpropanesulfonic acid, and of about 5% by weight of a nonionic monomer of the formula (I)
H2C?CH—CH2?O[EO]17—H  (I)
in which EO is ethylene oxide units;
between about 0.1 wt-% and about 50 wt-% water;
between about 65 wt-% and about 95 wt-% alkali metal carbonate; and
between about 0.5 wt-% and about 10 wt-% at least two surfactants, wherein the at least two surfactants are a fatty alcohol alkoxylate, and an EO/PO copolymer having terminal hydroxyl groups;
wherein the solid detergent composition is dimensionally stable and has a growth exponent of less than 3% if heated at a temperature of 122° F.
US Pat. No. 10,364,414

FILTER BASED SYSTEM FOR CAPTURE OF LYSIS OF SUSPENDED CELLS

LIFE TECHNOLOGIES CORPORA...

1. A cell lysis system comprising:a filter;
a reservoir in fluid communication with the filter and operatively positioned on a first side thereof;
a cell suspension intake in fluid communication with the filter and operatively positioned on the first side thereof;
a lysis solution intake in fluid communication with the filter and operatively positioned on a second side thereof; and
a reversible pump in fluid communication with the filter, wherein the reversible pump has a first operating state to cause fluid flow in a first flow direction through the filter from the first side toward the second side thereof, and a second operating state to cause fluid flow in a second flow direction through the filter from the second side toward the first side thereof;
wherein the cell suspension intake is configured to receive a cell suspension therethrough such that the cell suspension is filtered through the filter and a plurality of cells of the cell suspension are captured on the first side of the filter when the reversible pump is in the first operating state;
wherein the lysis solution intake is configured to receive a lysis solution therethrough such that the lysis solution passes through the filter in the second flow direction when the reversible pump is in the second operating state to lyse and suspend the plurality of cells captured on the first side of the filter to produce a cellular lysate; and
wherein the reservoir is configured to receive the cellular lysate when the reversible pump is in the second operating state.
US Pat. No. 10,364,160

PROCESS FOR PRODUCING POTASSIUM TITANATE

TOHO TITANIUM CO., LTD., ...

1. A method for producing a potassium titanate consisting essentially of:a mixing step that mixes a titanium raw material with a potassium raw material, the titanium raw material comprising 80 to 100 mass % of titanium oxide having a specific surface area of 7 to 50 m2/g, and 0 to 4.5 mass % in total of one or more materials selected from titanium metal and titanium hydride, and the potassium raw material comprising a potassium compound;
a calcination step that calcines a raw material mixture obtained by the mixing step at a calcination temperature of 950 to 990° C.;
a grinding step that grinds a calcined powder obtained by the calcination step using a vibrating mill and an impact pulverizer;
wherein after the calcination step, the method is performed without pH adjustment and without an acid wash;
the vibrating mill is at least one selected from a vibrating rod mill and a vibrating ball mill; and
the impact pulverizer is at least one selected from a high-speed rotary mill, high-speed rotary mill provided with a classifier, a media agitating mill, and a jet mill.
US Pat. No. 10,364,416

CANNABICHROMENIC ACID SYNTHASE FROM CANNABIS SATIVA

NATIONAL RESEARCH COUNCIL...

1. A method of modulating levels of cannabinoid compounds in an organism, cell or tissue, said method comprising:a) introducing a nucleic acid molecule comprising:
i) a nucleotide sequence complementary to a polynucleotide encoding at least a portion of a polypeptide having the sequence set for in SEQ ID NO: 2 or 6 or a polypeptide having at least 99.5% sequence identity to SEQ ID NO: 2 or 6; or
ii) a nucleotide sequence complementary to a polynucleotide having at least, greater than or about 99.5% sequence identity to at least a portion of SEQ ID NO: 1 or 5;
into the organism, cell or tissue to decrease the level of a cannabinoid compound,
wherein the portion comprises greater than, at least or about 15 contiguous nucleotides,
and wherein the nucleic acid molecule is comprised in a construct, to silence cannabichromenic acid synthase gene in the organism, cell or tissue to decrease the level of a cannabinoid compound; or
b) introducing a nucleic acid molecule or construct comprising said nucleic acid molecule, and expressing or over-expressing a polypeptide having cannabichromenic acid synthase activity encoded by said nucleic acid molecule, said nucleic acid molecule comprising
i) a nucleotide sequence encoding a polypeptide having the sequence set for in SEQ ID NO: 2 or 6 or a polypeptide having at least 99.5% sequence identity to SEQ ID NO: 2 or 6;
ii) a nucleotide sequence having at least, greater than or about 99.5% sequence identity to SEQ ID NO: 1 or 5; or
iii) a nucleotide sequence having at least, greater than or about 90% sequence identity to SEQ ID NO: 8 or 9;
in the organism, cell or tissue to increase the level of a cannabinoid compound.
US Pat. No. 10,364,417

INCREASED ALCOHOL TOLERANCE USING THE PNTAB GENE

The United States of Amer...

1. A transformed microorganism,wherein the transformed microorganism contains an alcohol tolerance gene,
wherein the transformed microorganism has a higher alcohol tolerance as compared to a non-transformed microorganism, and
wherein the alcohol tolerance gene is one of pntAB, pntA, and pntB,
wherein each of pntA, pntB, and pntAB is a transhydrogenase gene,
wherein the alcohol tolerance gene comprises a nucleotide sequence having at least 75% similarity to one of SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, and SEQ ID NO: 22, and
wherein the microorganism expresses at least one alcohol tolerance protein, the alcohol tolerance protein being at least one of PntA and PntB.
US Pat. No. 10,367,234

BATTERY HAVING INTEGRATED SAFETY CONTROLLER AND POWER MANAGEMENT CONTROLLER

Microsoft Technology Lice...

1. A battery, comprising:at least one battery cell; and
a printed circuit board (PCB) comprising a safety controller of the at least one battery cell and a power management controller of a device using a power of the battery;
wherein the power management controller comprises power outputs directly outputting a power of the battery to at least one module of the device; and
wherein the safety controller and the power management controller are integrated into the same PCB of the battery; and
wherein the at least one module comprises a display module, wherein the display module is configured to be stacked on top of the battery and comprises a flex having a connection interface of the display module, wherein the flex is configured on top of the PCB and the connection interface is configured to contact the PCB of the battery.
US Pat. No. 10,364,420

DIMERIC REVERSE TRANSCRIPTASE

BIO-RAD LABORATORIES, INC...

1. A polypeptide comprising a first reverse transcriptase and a second reverse transcriptase covalently linked by a heterologous linker, wherein the first reverse transcriptase and the second reverse transcriptase are identical.
US Pat. No. 10,364,421

MODIFIED GLUCOAMYLASE ENZYMES AND YEAST STRAINS HAVING ENHANCED BIOPRODUCT PRODUCTION

CARGILL, INCORPORATED, W...

1. A polypeptide comprising (a) a secretion signal amino acid sequence having 90% or greater identity to SEQ ID NO:10 or SEQ ID NO:11 and (b) a glucoamylase amino acid sequence from a yeast, fungal, or bacterial glucoamylase polypeptide, wherein the polypeptide has glucoamylase activity, andwherein the polypeptide comprises SEQ ID NO: 13.
US Pat. No. 10,365,189

HISTOLOGICAL SPECIMEN TREATMENT

1. A process for preserving a specimen comprising: using a dissolving compound that can form a plural number of azeotropes; successively and azeotropically vaporizing off the formed azeotropes, the first formed azeotrope being vaporized off by reducing pressure, followed by raising temperature to form the second azeotrope, the second azeotrope being vaporized off by reducing pressure, followed by raising temperature to form the third azeotrope, and the third azeotrope being vaporized off by reducing pressure; wherein a first azeotrope is formed between one or more components of the dissolving compound and specimen-supplied water, a second azeotrope is formed between different components of the dissolving compound, and a third azeotrope is formed between different components of the dissolving compound, the third azeotrope being different from the second azeotrope; and impregnating the specimen with a support medium.
US Pat. No. 10,364,422

CELLULASE ENZYMES HAVING A MODIFIED LINKER AND REDUCED LIGNIN BINDING

IOGEN ENERGY CORPORATION,...

1. A modified cellulase enzyme comprising a cellulase catalytic domain, a modified linker peptide, and a carbohydrate binding module, wherein the amino acid sequence of the modified linker peptide is:(a) a variant of the amino acid sequence of SEQ ID NO: 83 consisting of one or more amino acid substitutions of SEQ ID NO: 83, wherein the one or more amino acid substitutions is selected from the group consisting of G2D, S5T, S6T, S7T, S7N, S8T, S9T, S14T, S17T, S20T, S24T, S26T, S27T, S28T, G34D, S35T, T38A, and V43D of SEQ ID NO: 83, wherein the variant confers at least a 1.2-fold reduction in lignin binding to the modified cellulase enzyme relative to a cellulase enzyme comprising the same cellulase catalytic domain, a linker peptide consisting of the amino acid sequence of SEQ ID NO: 83, and the same carbohydrate binding module, or
(b) a variant of the amino acid sequence of SEQ ID NO: 39 consisting of one or more amino acid substitutions of SEQ ID NO: 39, wherein the one or more amino acid substitutions is selected from the group consisting of R12E and R13E of SEQ ID NO: 39, wherein the variant confers at least a 1.2-fold reduction in lignin binding to the modified cellulase enzyme relative to a cellulase enzyme comprising the same cellulase catalytic domain, a linker peptide consisting of the amino acid sequence of SEQ ID NO: 39, and the same carbohydrate binding module, and
wherein the modified linker peptide is positioned between the cellulase catalytic domain and the carbohydrate binding module and the modified cellulase enzyme exhibits cellulose-hydrolyzing activity.
US Pat. No. 10,364,423

POLYPEPTIDES HAVING BETA-XYLOSIDASE ACTIVITY AND POLYNUCLEOTIDES ENCODING SAME

Novozymes, Inc., Davis, ...

1. A process for degrading or converting a cellulosic or xylan-containing material, the process comprising: treating the cellulosic or xylan-containing material with an enzyme composition and a polypeptide having beta-xylosidase activity, and recovering the degraded or converted cellulosic material; wherein the polypeptide having beta-xylosidase activity is selected from the group consisting of:(a) a polypeptide having at least 95% sequence identity to amino acids 17 to 582 of SEQ ID NO: 6;
(b) a polypeptide encoded by a polynucleotide that hybridizes under very high stringency conditions with the full-length complement of nucleotides 49 to 1746 of SEQ ID NO: 5 or the cDNA of nucleotides 55 to 1763 SEQ ID NO: 3, wherein very high stringency conditions are defined as prehybridization and hybridization at 42° C. in 5×SSPE, 0.3% SDS, 200 micrograms/ml sheared and denatured salmon sperm DNA, and 50% formamide, and washing three times each for 15 minutes using 2×SSC, 0.2% SDS at 70° C.; and
(c) a polypeptide encoded by a polynucleotide having at least 99% sequence identity to nucleotides 49 to 1746 of SEQ ID NO: 5, or the cDNA of nucleotides 49 to 1746 of SEQ ID NO: 5.
US Pat. No. 10,363,400

METHOD TO MAKE TUBE-IN-TUBE BALLOON

BOSTON SCIENTIFIC SCIMED,...

1. A method of making an expandable medical balloon, comprising:disposing an adhesive layer on a tubular parison, the tubular parison comprising polyamide, poly(ether-block-amide), or a combination thereof; and
longitudinally pre-stretching the tubular parison from a first length to a second length; and
radially expanding the tubular parison in a balloon mold, wherein the radial expansion comprises pressuring the assembly at a temperature and a pressure above ambient temperature or up to about 50° C. so as to expand the parison into a medical balloon, the parison having a wall thickness Ta and the medical balloon having a wall thickness Tb.
US Pat. No. 10,364,424

FACTOR X MUTANTS

LABORATOIRE FRANCAIS DU F...

1. A protein, comprising:a mutated sequence of SEQ ID No. 1, said mutated sequence of SEQ ID No. 1 comprising mutation B wherein: mutation B consists of insertion of DFLAEGLTPR (SEQ ID NO: 159) between amino acids 52 and 53 of SEQ ID No. 1.
US Pat. No. 10,364,169

ULTRAFILTRATION TIO2 MAGNéLI PHASE REACTIVE ELECTROCHEMICAL MEMBRANES

The Board of Trustees of ...

1. A reactive electrochemical membrane comprisinga support layer having a median pore diameter size of 1 ?m to 10 ?m; and
an active layer disposed adjacent to and in contact with the support layer, and having a median pore diameter size of less than 1 ?m,wherein the median pore diameter of the support layer is at least 50% bigger than the median pore diameter of the active layer, andwherein the support layer and the active layer independently comprise at least 80 wt % oxides of titanium, and wherein the oxides of titanium comprise at least 80 wt % of one or more of Magnéli-phase titanium oxides of the formula TinO2n?1, wherein n is an integer 4, 5, or 6.
US Pat. No. 10,364,425

RECOMBINANT OR TRANSGENIC FACTOR VII COMPOSITION, EACH FACTOR VII MOLECULE HAVING TWO N-GLYCOSYLATION SITES WITH DEFINED GLYCAN UNITS

LABORATOIRE FRANCAIS DU F...

1. A composition comprising recombinant Factor VII (FVII), produced by a transgenic female rabbit,wherein each molecule of FVII of the composition exhibits glycan moieties and two N-glycosylation sites,
wherein among all the molecules of FVII of the composition, the proportion of Gal?1,3Gal glycan moieties is between 0 and 4%,
wherein the molecules of FVII of the composition do not comprise sialic acid bound in ?2-3 links,
wherein among all the glycan moieties bound to N-glycosylation sites of the FVII of the composition, more than 50% of the glycan moieties are biantennary, monosialylated, glycan moieties,
wherein the molecules of FVII of the composition exhibit two O-glycosylation sites at position Ser52 and Ser60
wherein the molecules of FVII of the composition exhibit nine ?-carboxylated N-terminal glutamic acids, and
wherein the molecules of FVII of the composition exhibit 12 specific disulfide bridges.
US Pat. No. 10,364,428

METHODS AND KITS FOR POST-IVT RNA PURIFICATION

Corning Incorporated, Co...

1. A method for nucleic acid purification, comprising:(a) combining a sample comprising at least one nucleic acid with a binding buffer having a pH ranging from about 4 to about 10 to form a solution;
wherein the binding buffer comprises at least one magnetic particle, at least one chaotropic agent, present in a concentration ranging from about 0.2 M to about 6 M, at least one first alcohol, present in a concentration ranging from about 0.1 M to about 5 M, and at least one first salt, present in a concentration ranging from about 10 mM to about 100 mM;
(b) incubating the solution for a time period sufficient to reversibly bind the at least one nucleic acid to the at least one magnetic particle to form at least one modified magnetic particle;
(c) separating the at least one modified magnetic particle from the combined solution;
(d) washing the at least one modified magnetic particle with at least one wash buffer comprising at least one second alcohol and optionally at least one second salt; and
(e) combining the at least one modified magnetic particle with an elution buffer.
US Pat. No. 10,364,429

METHODS AND COMPOSITIONS FOR CONTROLLING EFFICACY OF RNA SILENCING

UNIVERSITY OF MASSACHUSET...

1. A vector encoding an engineered pre-miRNA comprising a RNAi agent comprising a sense strand and an antisense strand that is complementary to a target sequence in a wild-type human mRNA, wherein at least five terminal nucleotides at the 3? end of the antisense strand are substituted with nucleotides which form G:U wobble base pairs with the corresponding nucleotides in the wild-type target human mRNA when compared with a reference antisense strand that is fully complementary to the target sequence, wherein the human mRNA encodes for an oncogene-encoded protein or a tumor suppressor protein.
US Pat. No. 10,364,430

IDENTIFICATION OF A JAK2 MUTATION IN POLYCYTHEMIA VERA

INSTITUT NATIONAL DE LA S...

1. A method for detecting a mutation in the JAK2 (Janus kinase 2) gene of a human patient, comprising:a) obtaining a nucleic acid sample from a human patient; and
b) detecting a thymine (T) in the JAK2 gene at position 2343 of SEQ ID NO: 2 in the nucleic acid sample by:
a1) sequencing a region of the nucleic acid sample comprising position 2343 of SEQ ID NO: 2, or
a2) hybridizing the nucleic acid sample with at least one probe or primer comprising at least 10 consecutive nucleotides of SEQ ID NO: 2 comprising position 2343 of SEQ ID NO: 2, or with a complement of said probe or primer.
US Pat. No. 10,364,431

COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY

Sarepta Therapeutics, Inc...

1. A method for treating Duchenne muscular dystrophy (DMD) in a patient in need thereof who has a mutation of the DMD gene that is amenable to exon 51 skipping, comprising intravenously administering to the patient a composition comprising eteplirsen, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein eteplirsen, or a pharmaceutically acceptable salt thereof, is administered at a dose of about 30 mg/kg once a week for more than 120 weeks, such that disease progression in the patient is delayed, thereby treating the patient.
US Pat. No. 10,364,432

ANTISENSE OLIGONUCLEOTIDE DIRECTED REMOVAL OF PROTEOLYTIC CLEAVAGE SITES FROM PROTEINS

Academisch Ziekenhuis Lei...

1. A method of promoting production of a human Huntingtin protein lacking a proteolytic caspase-6 cleavage site in a human cell, the method comprising:a) providing a human cell that expresses a human Huntingtin protein comprising a caspase-6 proteolytic cleavage site from a pre-mRNA encoding the protein, with an antisense oligonucleotide that
is directed toward the interior of exon 12 of the human Huntingtin gene;
binds to the pre-mRNA to form a double-stranded nucleic acid complex; and
induces partial skipping of exon 12,wherein at least nucleotides 207 to 341 of exon 12 are skipped;wherein each nucleotide of the antisense oligonucleotide is chemically modified to render the double-stranded nucleic acid complex RNase H resistant; andb) allowing translation of mRNA produced from the pre-mRNA in the cell to produce an mRNA lacking nucleotides 207 to 341 of exon 12;wherein the anti-sense oligonucleotide comprises or consists of a sequence selected from SEQ ID NO:178 and 182.
US Pat. No. 10,363,153

SUPERFINE POLYESTER FIBER AND TUBULAR SEAMLESS FABRIC

ASAHI KASEI FIBERS CORPOR...

1. A fabric having a plain weave structure or twill weave structure of a superfine polyester fiber and comprising at least 20 wt % of said superfine polyester fiber, said superfine polyester fiber having a polyethylene terephthalate component content of 98 wt % or greater, and satisfying the following requirements:(1) a reduced viscosity (?sp/c) of 0.80 dl/g or greater,
(2) a total fineness of between 7 dtex and 120 dtex, inclusive, and a single filament fineness of 0.5 dtex or less,
(3) a toughness parameter X of 2.0 or greater as represented by the following formula (1):
X=(tensile strength×?tensile elongation)/(total fineness×single filament fineness)
Formula (1), wherein tensile strength is expressed in CN/dtex, tensile elongation is expressed in %, and fineness is expressed in dtex,
a tensile strength of 3.5 cN/dtex or greater and a tensile elongation of 12% or greater;
wherein the fabric has a thickness of between 10 ?m and 90 ?m, inclusive.
US Pat. No. 10,364,177

GLASS COMPOSITIONS HAVING HIGH THERMAL AND CHEMICAL STABILITY AND METHODS OF MAKING THEREOF

Corning Incorporated, Co...

wherein:(i) the glass satisfies the relationship:
1.15??(MgO+CaO+SrO+BaO)/(Al2O3)?1.50,where Al2O3, MgO, CaO, SrO, and BaO represent the mole percents of the respective oxide components,(ii) when the glass comprises the optional component SrO, the glass satisfies the relationship:
BaO/SrO?2.0,where BaO and SrO represent the mole percents of the respective oxide components,(iii) the amount of any oxide in the glass other than SiO2, Al2O3, B2O3, MgO, CaO, SrO, BaO, and La2O3 is less than or equal to 2.0 mole percent,
(iv) the glass has a strain point greater than or equal to 700° C.,
(v) the glass exhibits a dimensional change of less than 30 ppm for a 5 minute heat treatment at 600° C., and
(vi) the glass has a Young's modulus to density ratio greater than or equal to 28.0 GPa·cm3/g.
US Pat. No. 10,364,433

MODULATION OF AGPAT5 EXPRESSION

The Regents of the Univer...

1. A method of reducing insulin, glucose, and/or free fatty acid levels in blood, triglyceride levels in the liver and/or the ratio of fat to body weight of an animal comprising administering a compound comprising an antisense oligonucleotide targeted to nucleic acid encoding human AGPAT5 wherein the level of insulin, glucose and/or free fatty acid in the blood, the level of triglycerides in the liver and/or the ratio of fat to body weight of the animal is/are reduced.
US Pat. No. 10,364,178

GLASSES HAVING IMPROVED TOUGHNESS AND SCRATCH RESISTANCE

CORNING INCORPORATED, Co...

1. A silicate glass, the silicate glass being ion exchangeable and comprising:62-70 mol % SiO2;
0-18 mol % Al2O3;
>0-10 mol % B2O3;
>0-15 mol % Li2O;
6-20 mol % Na2O;
0-18 mol % K2O;
>0-17 mol % MgO;
ZrO2; and
SnO2,
wherein 10 mol %?Al2O3+B2O3+ZrO2?30 mol %, and
wherein 14 mol %?R2O+R?O?25 mol %, where R is at least one of Li, Na, K, Rb, and Cs, and R? is at least one of Mg, Ca, Sr, and Ba, and
wherein ?15 mol %?(R2O+R?O?Al2O3?ZrO2)?B2O3?4 mol %.
US Pat. No. 10,364,435

IMMUNIZATION AND/OR TREATMENT OF PARASITES AND INFECTIOUS AGENTS BY LIVE BACTERIA

1. A genetically engineered chimeric peptide, comprising:a therapeutic peptide portion selected from the group consisting of:
a Bacillus thuringiensis toxin,
a Photorhabdus species insecticidal cytotoxin,
a Xenorhabdus species insecticidal cytotoxin,
anthelmintic cyclic heptapeptide segetalin D, and
a cyclodepsipeptid,
effective to provide a selective cytotoxic therapy of a parasitic disease caused by a parasite, the therapeutic peptide portion being toxic to the parasite;
a targeting peptide portion comprising a parasite targeting (binding) peptide, effective to selectively target the therapeutic peptide portion to at least one cell of the parasite; and
a secretion peptide portion selected from the group consisting of an autotransporter peptide, an HlyA peptide, an HlyB peptide, a type I secretion system active peptide, a type III secretion system active peptide, a colicin release peptide, a bacteriophage release peptide, Lpp-OmpA fusion, M13pIII, and a C-terminal RTC protein, effective to cause secretion of the chimeric peptide from a genetically engineered microorganism which produces the chimeric peptide,
wherein the therapeutic peptide portion, the targeting peptide portion, and the secretion peptide portion of the chimeric peptide are derived by gene fusion from different genes.
US Pat. No. 10,364,436

COMPOSITIONS AND METHODS FOR CLOSTRIDIAL TRANSFORMATION

Danisco US Inc., Palo Al...

1. A recombinant Clostridium bacterial cell comprising:a) a plasmid comprising the sequence of SEQ ID NO: 14, and
b) at least one shuttle plasmid comprising the sequence of any one of SEQ ID NOs: 15-20, wherein the shuttle plasmid further comprises one or more nucleic acid(s) of interest.
US Pat. No. 10,364,181

ANTIMICROBIAL ARTICLES WITH SILVER-CONTAINING ALKALI SILICATE COATING AND METHODS OF MAKING THEREOF

CORNING INCORPORATED, Co...

10. An antimicrobial article comprising:a substrate; and
a coating on a surface of the substrate, the coating comprising at least one of a silver-containing alkali aluminosilicate and a silver-containing alkali borosilicate,
wherein the antimicrobial article has an antimicrobial efficacy of greater than or equal to about 90.0% according to EPA Test Method for Efficacy of Copper Alloy Surfaces as a Sanitizer.
US Pat. No. 10,364,437

PLANT GENES INVOLVED IN NITRATE UPTAKE AND METABOLISM

Iowa State University Res...

1. A method of expressing a nucleic acid molecule up-regulated by nitrogen in a plant, said method comprising:providing a transgenic plant or plant cell transformed with a nucleic acid construct, wherein the nucleic acid construct comprises:
a nucleic acid molecule that is up-regulated in corn by nitrogen;
a 5? DNA promoter sequence, wherein the DNA promoter sequence is a nitrogen inducible plant promoter; and
a 3? terminator sequence, wherein the nucleic acid molecule, the DNA promoter sequence, and the terminator sequence are operatively linked to permit transcription of the nucleic acid molecule, and wherein the nucleic acid molecule:
(a) encodes a polypeptide having the amino acid sequence of SEQ ID NO:43; or
(b) comprises the nucleotide sequence of SEQ ID NO:42; or
(c) comprises the coding portion of the nucleotide sequence of SEQ ID NO:42; and
growing the transgenic plant or a plant grown from the transgenic plant cell under conditions effective to express the nucleic acid molecule in said transgenic plant or said plant grown from the transgenic plant cell.
US Pat. No. 10,364,183

COMPOSITE COMPRISING A MINERAL WOOL COMPRISING A SUGAR

SAINT-GOBAIN ISOVER, Cou...

1. A process for preparing a shaped composite, the process comprising:mixing fragments of mineral wool sized with a sizing composition comprising a sugar with a non-cement silica carrier distinct from the wool, a non-cement alkali metal carrier distinct from the wool, and water, to obtain a mixture, wherein the non-cement silica carrier and the non-cement alkali metal carrier form, with the water, a mineral binder that gradually solidifies around solid particles present in the mixture; and then
shaping the mixture into a shaped composite.
US Pat. No. 10,364,439

PESTICIDAL GENES AND METHODS OF USE

AGBIOME, INC., Research ...

19. A method for increasing yield in a plant, said method comprising growing in a field a plant or seed thereof having stably incorporated into its genome a DNA construct comprising a promoter that drives expression in the plant operably linked to a nucleotide sequence that encodes a pesticidal polypeptide, wherein said nucleotide sequence comprises(a) a nucleotide sequence that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:79; or
(b) a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:79, wherein said polypeptide has pesticidal activity against at least one of Lepidopteran or Coleopteran pests.
US Pat. No. 10,364,184

MANUFACTURING METHOD OF BIG-MODEL LOW-PERMEABILITY MICROCRACK CORE

SOUTHWEST PETROLEUM UNIVE...

1. A manufacturing method of a big-model low-permeability microcrack core, comprising the following steps successively:(1) determining a size of a microcrack core to be manufactured;
(2) placing a plurality of stones in a baking oven to bake for 24 h under 120° C., after baking, placing the plurality of stones into a mixer, mixing and spraying an oil, and keeping the mixture of the plurality of stones and the oil for 2 h after mixing evenly to enable the oil to seep into the plurality of stones and evenly forming a layer of thin oil film on a surface of the plurality of stones;
(3) mixing the plurality of stones sprayed by the oil in step (2) with a quartz sand and a cement, and then adding water and mixing evenly to obtain a cement paste;
(4) spreading a butter on an inner surface of a core mould to form a layer of thin butter film on the inner surface of the core mould, pouring the cement paste in step (3) into the core mould, and vibrating the cement paste in the core mould by a vibrating rod during pouring to obtain a cement sample;
(5) loading a predetermined confining pressure outside the core according to a degree of porosity of the mould and the permeability after pouring, so as to adjust a pore permeability value; and
(6) forming the big-model low-permeability microcrack core after drying the cement sample.
US Pat. No. 10,364,442

CRISPR ENABLED MULTIPLEXED GENOME ENGINEERING

The Regents of the Univer...

1. A method for tracking a multitude of genome edits in a cell population, comprising:a) introducing into a first population of cells a first vector that encodes:
(i) at least one editing cassette wherein the at least one editing cassette comprises
a) a region homologous to a target region of a nucleic add and comprising a mutation of at least one nucleotide relative to the target region, and
b) a mutation preventing nuclease binding at a protospacer adjacent motif (PAM);
(ii) at least one promoter; and
(iii) a region encoding at least one guide RNA comprising a region complementary to the target region, thereby producing a second population of cells that comprise the first vector;
b) maintaining the second population of cells under conditions n which a nuclease is expressed thereby producing a cell library that comprises a genome edit and comprises the mutation preventing nuclease binding at the PAM; and
c) tracking the multitude of genome edits in the cell library by sequencing the editing cassette of the first vector from at east one cell in the cell library or sequencing the target region of at least one cell in the cell library.
US Pat. No. 10,364,443

PRODUCTION OF MEVALONATE, ISOPRENE, AND ISOPRENOIDS USING GENES ENCODING POLYPEPTIDES HAVING THIOLASE, HMG-COA SYNTHASE AND HMG-COA REDUCTASE ENZYMATIC ACTIVITIES

Danisco US Inc., Palo Al...

1. Recombinant cells with increased production of mevalonate, the cells comprising one or more heterologous nucleic acids comprising a mevalonate E (mvaE) gene and a mevalonate S (mvaS) gene selected from the organisms Listeria grayi (L. grayi), Enterococcus faecium (E. faecium), Enterococcus gallinarum (E. gallinarum), and Enterococcus casseliflavus (E. casseliflavus),wherein the mvaE gene and mvaS gene encode polypeptides having thiolase, HMG-CoA synthase, and HMG-CoA reductase catalytic activities, and wherein the cells produce increased amounts of mevalonate compared to mevalonate-producing cells that (A) contain an mvaE gene and mvaS gene from Enterococcus faecalis (E. faecalis) and (B) do not contain said mvaE gene and mvaS gene from E. gallinarum, E. casseliflavus, E. faecium, or L. grayi.
US Pat. No. 10,364,444

SACCHAROMYCES CEREVISIAE YEAST STRAINS AND METHODS OF USE THEREOF

Microbiogen Pty. Ltd., S...

1. A process for producing ethanol from starch-containing material, the process comprising the steps of:i) liquefying the starch-containing material at a temperature above the initial gelatinization temperature using an alpha-amylase;
ii) saccharifying using a glucoamylase;
iii) fermenting using a fermenting organism;wherein the fermenting organism is:Saccharomyces cerevisiae MBG4930 (deposited under Accession No. V15/004035 at National Measurement Institute, Victoria, Australia);
Saccharomyces cerevisiae MBG4931 (deposited under Accession No. V15/004036 at National Measurement Institute, Victoria, Australia); or
Saccharomyces cerevisiae MBG4932 (deposited under Accession No. V15/004037 at National Measurement Institute, Victoria, Australia).
US Pat. No. 10,364,445

PROCESSES OF PRODUCING FERMENTATION PRODUCTS

1. A method of dewatering whole stillage comprising:(a) liquefying a starch-containing material with an alpha-amylase; optionally pre-saccharifying the liquefied material before step (b);
(b) saccharifying the liquefied material;
(c) fermenting using a fermentation organism;
(d) separating the fermented material into a fermentation product and whole stillage;
(e) dewatering the whole stillage;
wherein a carbohydrate-source generating enzyme and a cellulolytic composition comprising a beta-glucosidase having a Relative ED50 loading value of less than 1.00 are present or added during the optional presaccharification step, saccharification step (b), and/or fermentation step (c), or simultaneous saccharification and fermentation, and wherein the beta-qlucosidase is the Aspergillus fumiqatus beta-qlucosidase of SEQ ID NO: 6 or a variant thereof having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 6 and which comprises one or more substitutions selected from the group consisting of L89M, G91L, F100D, I140V, I186V, S283G, N456E, and F512Y.
US Pat. No. 10,365,213

RELIABLE FLUORESCENCE CORRECTION METHOD FOR TWO-COLOR MEASUREMENT FLUORESCENCE SYSTEM

CapitalBio Corporation, ...

1. A microarray chip for use in a two-color fluorescence measurement system, comprising three kinds of standard spots separate from each other on the microarray chip that are useful for determining correction factors for fluorescence measurements with the system, wherein the three standard spots comprise:standard spot 1 comprising the donor fluorophore and none of the acceptor fluorophore used in the two-color fluorescence measurement system, wherein the donor fluorophore is immobilized on the microarray chip,
standard spot 2 comprising the acceptor fluorophore and none of the donor fluorophore used in the two-color fluorescence measurement system, wherein the acceptor fluorophore is immobilized on the microarray chip,
wherein the acceptor fluorophore in standard spot 2 is present in the same molar amount as the donor fluorophore in standard spot 1, and
standard spot 3 comprising both the donor and the acceptor fluorophores immobilized on the microarray chip, wherein the molar amount of the donor fluorophore in standard spot 3 equals the molar amount of the acceptor fluorophore in standard spot 3.
US Pat. No. 10,364,192

METHOD FOR FORMING SINTERED CERAMIC MATERIAL

King Fahd University of P...

1. A process for forming a sintered Ca-SiAlON ceramic containing aluminum particles, comprising:mixing
calcium oxide;
silicon nitride;
alumina;
aluminum nitride; and
1.8 wt % to 10 wt % of aluminum particles to form a powder mixture, wherein wt % is based on the total weight of the powder mixture;
spark plasma sintering the powder mixture under a uniaxial pressure of from 20 to 55 MPa to form the sintered Ca-SiAlON ceramic; and
cooling the sintered Ca-SiAlON ceramic to a temperature ranging from 20-40° C.
US Pat. No. 10,364,449

FERMENTATIVE PRODUCTION OF OLIGOSACCHARIDES

1. A method for producing difucosyllactose, said method comprising the step of culturing, in a culture medium containing an exogenously added acceptor and a genetically modified E. coli of LacY+ genotype having a H. pylori futC gene that encodes an ?-1,2-fucosyl transferase that is (a) capable of modifying said acceptor and (b) is necessary for the synthesis of said difucosyllactose from said acceptor wherein the acceptor consists of 2?-O-fucosyllactose.
US Pat. No. 10,364,450

PRODUCTION OF STEVIOL GLYCOSIDE IN RECOMBINANT HOSTS

EVOLVA SA, Reinach (CH)

1. A recombinant host cell capable of producing a steviol glycoside, a glycosylated ent-kaurenol compound, and/or a glycosylated ent-kaurenoic acid compound in a cell culture, comprising a gene encoding a polypeptide capable of selectively converting rubusoside to stevioside and having 95% or greater sequence identity to the amino acid sequence set forth in SEQ ID NO:17 or 18 and a first gene encoding a first polypeptide capable of beta 1,2 glycosylation of the C2? of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the steviol glycoside and having 95% or greater sequence identity to the amino acid sequence set forth in SEQ ID NO:16; wherein the recombinant host cell further comprises one or more of:(a) a second gene encoding a second polypeptide capable of beta 1,2 glycosylation of the C2? of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the steviol glycoside,
having 95% or greater sequence identity to the amino acid sequence set forth in SEQ ID NO:11;
(b) a gene encoding a polypeptide capable of glycosylating steviol or the steviol glycoside at its C-13 hydroxyl group
having 95% or greater sequence identity to the amino acid sequence set forth in SEQ ID NO:7; and
(c) a gene encoding a polypeptide capable of beta 1,3 glycosylation of the C3? of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the steviol glycoside
having 95% or greater sequence identity to the amino acid sequence set forth in SEQ ID NO:9; or
(d) a gene encoding a polypeptide capable of glycosylating steviol or a steviol glycoside at its C-19 carboxyl group, wherein the polypeptide comprises a polypeptide having 95% or greater sequence identity to the amino acid sequence set forth in SEQ ID NO:4;
wherein at least one of the genes is a recombinant gene.
US Pat. No. 10,364,451

POLYMER CONJUGATES HAVING REDUCED ANTIGENICITY AND METHODS OF USING THE SAME

Duke University, Durham,...

1. A method of reducing the antigenicity of a molecule, the method comprising conjugating at least one branched polymer to a molecule to form a molecule-polymer conjugate,wherein the molecule comprises a polypeptide, a polynucleotide, a small molecule, or a combination thereof,
wherein the branched polymer comprises poly[oligo(ethylene glycol) methyl ether methacrylate] (POEGMA),wherein the POEGMA comprises:a backbone comprising poly(methyl methacrylate); and
a plurality of side chains covalently attached to the backbone, where each side chain comprises 2 to 9 monomers of ethylene glycol (EG) repeated in tandem;
wherein the molecule-polymer conjugate is not reactive with pre-existing anti-PEG antibodies in a subject, and
wherein the molecule-polymer conjugate has reduced or eliminated antigenicity compared to a control.
US Pat. No. 10,364,196

MULTI-FUNCTIONAL COATING SYSTEM FOR CEMENTITIOUS COMPOSITE MATERIALS

James Hardie Technology L...

1. A multi-functional coating formulation for cementitious composite materials containing hydroxyl functional groups, comprising:50% to 60% by weight of a thermoplastic polymer binder comprising an epoxy ester dispersion containing at least one reactive functional group, the thermoplastic polymer binder comprising a non-crosslinking polymer capable of bonding to the hydroxyl functional groups in the cementitious composite material in a manner so as to form a sealing film on a surface of the composite material;
25% to 35% by weight of a functional pigment dispersed in the thermoplastic polymer binder, the functional pigment being rutile TiO2 having an average particle size greater than 5 microns (?m) and less than 12 microns (?m), wherein the pigment volume concentration of the rutile TiO2 in the coating formulation is about 30%, said functional pigment formulated with an oil absorption level of less than or equal to 17, wherein the oil absorption level in combination with the pigment volume concentration provide the coating formulation with blocking resistance;
10% to 20% by weight of deionized water; and
wherein the coating formulation functions as both a sealer and a primer for the cementitious composite material.
US Pat. No. 10,365,220

SINGLE-CELL RAMAN SPECTROSCOPY FOR THE NON-DESTRUCTIVE, NON-INVASIVE ANALYSIS OF CELLS AND CELLULAR COMPONENTS

LAWRENCE LIVERMORE NATION...

1. A method for non-destructively characterizing a cell, the method comprising:providing a sample comprising at least one intact cell in a solution, wherein the at least one intact cell is a white blood cell;
optically trapping a single intact cell from the sample using a laser using an excitation wavelength selected from the group of about 800-1800 nm, 780-950 nm, and 780-800 nm, wherein the excitation wavelength is selected to minimize the deleterious effects of heating the single intact cell;
illuminating the single intact trapped cell with the laser to generate a Raman spectrum, wherein the laser is not deleterious to the single intact trapped cell;
analyzing the Raman spectrum to characterize the single intact trapped cell;
identifying the single intact trapped cell as normal or abnormal based on the analyzed Raman spectrum; and
if the single intact trapped cell is identified as abnormal, removing the trapped intact abnormal cell from the sample using the laser.
US Pat. No. 10,364,453

DETECTING OF BACTERIA USING FLUORESCENTLY-LABELED PHAGE IMMOBILIZED ON AN OPTICALLY TRANSPARENT SURFACE

The United States of Amer...

1. A method for detecting bacteria in a sample, said method comprising the steps of:A) selecting a phage that is known to react with said bacteria to be detected said phage having nucleic acid;
B) immobilizing said phage head down on a transparent substrate;
C) tagging said phage nucleic acid with a fluorescent nucleic acid tag;
D) illuminating said phage from said step C) with a light source;
E) establishing a baseline fluorescence intensity for said illuminated phage from said step D);
F) exposing said tagged phage from said step C) to said sample to allow said tagged phage to lyse said bacteria;
F1) removing said substrate from said step F) from said sample;
G) illuminating said substrate from said removing step to establish a test fluorescence intensity;
H) comparing said test fluorescence intensity to said baseline fluorescence intensity, and,
I) deeming said bacteria to be present in said sample when said test fluorescence intensity is less than said baseline fluorescence intensity.
US Pat. No. 10,364,198

HEAVY PETROLEUM RESIDUE DERIVED IRON INCORPORATED SP2 CARBON NANOGRANULES FOR IMPROVED SYNTHESIS OF LIGHT OLEFINS

1. An Iron incorporated sp2 carbon nanogranules (Fe/CNG) catalyst comprising:(a) iron in the form of Fe(0), in bulk phase,
(b) iron in the form of Fe(0) along with Fe3C phase; and
(c) trace amounts of Fe(II) and Fe(III),wherein (a), (b) and (c) are collectively present in the range from 5 to 20 w/w % of the sp2 carbon nanogranules, and wherein the trace amounts of Fe(II) and Fe(III) are found on a surface of the sp2 carbon nanogranules.
US Pat. No. 10,364,455

METHODS AND COMPOSITIONS FOR IMPROVING REMOVAL OF RIBOSOMAL RNA FROM BIOLOGICAL SAMPLES

BIOO Scientific Corporati...

1. A method for removing 28S rRNA from an RNA sample comprising:obtaining an RNA sample from a biological source, said RNA sample containing 28S rRNA;
mixing said RNA sample with one or more RNA subtractive hybridization probes, thereby forming a mixture comprising the RNA sample and the one or more RNA subtractive hybridization probes, wherein the one or more RNA subtractive hybridization probes comprise an affinity label, and wherein the one or more of the RNA subtractive hybridization probes hybridize to two or more discontinuous regions of the 28S rRNA in the RNA sample but do not hybridize to GC rich regions of the 28S rRNA;
incubating the mixture under conditions effective to allow hybridization of the one or more RNA subtractive hybridization probes with the 28S rRNA in the RNA sample, thereby forming a hybridized complex comprising the one or more RNA subtractive hybridization probes and the 28S rRNA;
incubating the hybridized complex with a solid support in a reaction composition containing components that facilitate association of the hybridized complex with the solid support, thereby forming a complex comprising the hybridized complex and the solid support, wherein the affinity label on the one or more RNA subtractive hybridization probes of the hybridized complex specifically binds to an affinity label recognition molecule attached to the solid support; and
removing the 28S rRNA from the RNA sample by removing the complex comprising the hybridized complex and the solid support from the reaction composition.
US Pat. No. 10,362,922

ADSORPTION OF PARTICLES ON A MATERIAL CONTAINING A SILICONE POLYMER

Wacker Chemie AG, Munich...

1. A method for adsorption of particles by triboelectric charging, comprising adsorbing the particles on a material M which comprises an organic polymer material with silicone polymer(s) finely distributed therein, wherein the content of the silicone polymer in the material M is at least 0.0001 wt. % and less than 10 wt. % and wherein said silicon polymer comprises UHMW polysiloxane (ultra-high molecular weight silicone) having a dynamic viscosity from 1 kPa·s to 50 kPa·s at 25° C.
US Pat. No. 10,364,205

METHOD FOR PRODUCING KETONE AND/OR ALCOHOL, AND SYSTEM THEREOF

UBE INDUSTRIES, LTD., Ub...

1. A method for producing a ketone and/or alcohol by decomposing a hydroperoxide and an ester compound in an oxidation reaction solution obtained from oxidizing a hydrocarbon compound with molecular oxygen, in which the ketone and/or alcohol has the same number of carbon atoms as the hydrocarbon compound; wherein the method comprises:neutralizing at least a part of a carboxylic acid in the oxidation reaction solution by contacting the oxidation reaction solution with a first alkaline solution comprising a carbonate of an alkali metal, and separating the reaction mixture into a first oil phase and a first water phase, wherein a content of the hydroperoxide in the first oil phase is more than 90% of a content of the hydroperoxide in the oxidation reaction solution, and a pH of the first water phase is 8.5 or more and 9.55 or less;
decomposing the hydroperoxide and the ester compound in the first oil phase by contacting the first oil phase with a second alkaline solution having a higher pH value than the first alkaline solution, and separating the reaction mixture into a second oil phase and a second water phase, wherein a pH of the second water phase is greater than or equal to the pKa of the hydroperoxide and 14.0 or less;
recovering at least a part of an unreacted hydrocarbon from the second oil phase;
obtaining the ketone and/or alcohol from the second oil phase after recovering at least a part of the unreacted hydrocarbon by purification;
recycling a part or all of the second water phase as a part of the first alkaline solution; and
recovering the carbonate of an alkali metal from the first water phase and recycling the carbonate of an alkali metal to the first alkaline solution.
US Pat. No. 10,364,207

PROCESSES FOR OBTAINING MICROBIAL OIL FROM MICROBIAL CELLS

DSM IP Assets B.V., Te H...

1. A process for obtaining a microbial oil comprising one or more polyunsaturated fatty acids from one or more microbial cells, wherein the process comprises:(a) lysing the cells comprising the microbial oil to form a lysed cell composition;
(b) demulsifying the lysed cell composition to form a demulsified lysed cell composition;
(c) separating the oil from the demulsified lysed cell composition; and
(d) recovering the oil;
wherein (b) comprises adding at least one enzyme selected from the group consisting of beta-glucanase, xylanase, cellulase, pectinase, mannanase, amylase, and combinations thereof, and wherein at least one of (a) or (b) further comprises heating the cells or the composition to at least 60° C.
US Pat. No. 10,364,208

OXIDATIVE COUPLING OF ARYL BORON REAGENTS WITH SP3-CARBON NUCLEOPHILES, AND AMBIENT DECARBOXYLATIVE ARYLATION OF MALONATE HALF-ESTERS VIA OXIDATIVE CATALYSIS

The Governors of the Univ...

1. A method for decarboxylative carbonyl ?-arylation, comprising: reactinga. an aryl coupling partner,
b. a beta-carbonyl carboxylic acid, and
c. a copper based catalyst
the reaction taking place at room temperature, exposed to air, thereby creating a carbon-carbon bond.
US Pat. No. 10,364,465

REAGENTS AND METHODS FOR SEQUENCING

Life Technologies Corpora...

1. A single nucleic acid molecule comprising at least one reference sequence and multiple variants of the at least one reference sequence,wherein the nucleotide sequences of the at least one reference sequence and each variant are defined,
wherein the at least one reference sequence and variants are arranged within the single nucleic acid molecule as cassettes,
wherein within each cassette the at least one reference sequence is operably linked to one or more of a restriction enzyme site(s), and/or hairpin-forming site(s),
wherein each variant is at least 50% identical to the reference sequence, and wherein the single nucleic acid molecule comprises at least 15 variants.
US Pat. No. 10,363,700

BIORIENTED POLYETHYLENE FILM

Dow Global Technologies L...

1. A process for forming a biaxially oriented film comprising the steps of:a. selecting a polyolefin resin, wherein said polyolefin resin comprises a linear low density polyethylene resin characterized by having from 9 to 35 weight percent of the total weight of the linear low density polyethylene resin eluting from a crystallization elution fractionation (CEF) at a temperature greater than 97.0° C., a comonomer distribution ratio (CDR) of from 33 to 80, and a molecular weight ratio (Mw Ratio) of from 0.15 to 0.45;
b. forming a film from the polyolefin resin selected in step (a); and
c. biaxially orienting the film formed in step (b),
wherein the resulting film after said orienting in step (c) is characterized by having an ultimate elongation which is at least 1.5 times greater in the machine direction (MD) of the film as compared to the cross direction (CD) of the film and a 2% secant modulus of at least 1.25 times greater in the CD as compared to the MD,
wherein the resulting film after said orienting in step (c) is further characterized by having free residual shrinkage of less than 10% in the MD and less than 10% in the CD when exposed to a temperature of 90° C. for 10 minutes,
and wherein the polyolefin resin selected in step (a) permits use of applied temperature and stretching ratio conditions for said orientation step (c) to be chosen within a relatively broad range during the orienting process without a substantial loss in quality of the bioriented film, as compared to a film formed with a polyethylene resin which does not have the CEF, CDR, and Mw Ratio parameters of the polyolefin resin selected in step (a).
US Pat. No. 10,364,469

GENE EXPRESSION PANEL FOR PROGNOSIS OF PROSTATE CANCER RECURRENCE

ILLUMINA, INC, San Diego...

1. A method for treating a patient with prostate cancer, the method comprising:obtaining a biological sample from the patient, wherein the biological sample comprises a prostate tissue sample,
detecting expression levels of a collection of genes from the biological sample, wherein detecting expression levels of the collection of genes comprises hybridizing probes specific for each of the genes to nucleic acid molecules derived from the biological sample, wherein the collection of genes comprises a collection of signature genes, and
wherein said collection of signature genes comprises NKX2-1 and ABCC11;
correlating expression levels of said collection of signature genes with prostate-cancer related mortality to identify whether the patient is at risk of prostate-cancer related mortality; and
treating a patient at risk of prostate-cancer related mortality with one or more of radical prostatectomy, brachytherapy of the prostate, radiotherapy of the prostate, neoadjuvant hormone therapy for treating prostate cancer, and adjuvant hormone therapy for treating prostate cancer.
US Pat. No. 10,364,214

METHOD FOR PRODUCING ISOCYANATES

Covestro Deutschland AG, ...

15. A plant (10 000) for preparation of an isocyanate (1) by phosgenation of the corresponding amine (2), comprising:0) optionally an apparatus (4000) for production of phosgene (3) by reaction of carbon monoxide (300) with chlorine (310), giving an offgas stream (320) comprising carbon monoxide and phosgene;
I) a reaction zone (1000) comprising a reaction space (1200) for performance of the phosgenation, with a separation unit (1210) optionally connected downstream thereof, where the reaction space or the separation unit are provided with outlet conduits for a liquid stream (60) and a gaseous stream (70);
II) a distillation apparatus (2100) for separating the liquid stream (60) into a liquid stream (80) and a gaseous stream (90);
III) optionally a distillation apparatus (2200) for separating the liquid stream (80) into a gaseous stream (110) and a liquid stream (100);
IV) optionally a distillation apparatus (2300) for separating the gaseous stream (110), optionally after its liquefaction in a condenser (2310), into a liquid stream (120) and a gaseous stream (130);
V) optionally a distillation apparatus (2400) for obtaining a liquid isocyanate stream (140) from the liquid stream (100), resulting in a gaseous stream (150) comprising secondary components and optionally solvent, optionally comprising an upstream unit for polymer removal (2410) for removal of polymeric isocyanate fractions (141);
VI) an apparatus for absorption (2500) of the gaseous streams (70) and (90) and, if present, of the gaseous stream (130), optionally after passing through units (2510) for condensation connected upstream of the apparatus for absorption (2500), in solvent (4) to obtain a liquid stream (160) and a gaseous stream (170);
VII) an apparatus for absorption (2600) of the gaseous stream (170) in water or hydrochloric acid, optionally comprising a vapor condenser (2610), to obtain a stream (190) comprising hydrochloric acid and optionally solvent and a gaseous stream (200) comprising solvent and optionally gaseous secondary components;
VIII) an apparatus for workup of offgas streams (3000), comprising
VIII-1) an apparatus for catalytic phosgene decomposition (3010) for the decomposition of phosgene present in stream (200) and optionally also for the decomposition of phosgene present in stream (320) to obtain a gaseous stream (210) comprising solvent and optionally gaseous secondary components;
VIII-2) an adsorption apparatus (3020) for adsorption of solvent from stream (210), wherein the adsorption apparatus (3020) comprises at least two adsorption units (3021, 3022) connected in parallel, which are configured such that they can alternately be
(i) charged with stream (210) and
(ii) regenerated with steam;
IX) an apparatus for offgas combustion (6000) for combustion of the gas stream (220) obtained in VIII-2) (i); and
X) units for recycling of solvent desorbed in process stage VIII-2) (ii) into the reaction zone (1000) and/or into the apparatus for absorption (2500).
US Pat. No. 10,364,470

LONG NON-CODING RNA EXPRESSED IN AGGRESSIVE CANCER

The Regents of the Univer...

7. A method of detecting the level of expression of an RNA version of the SAILOR sequence SEQ ID NO: 2 in a human tissue sample, wherein the method comprises performing a quantitative reverse transcriptase-PCR (RT-PCR) on RNA obtained from the human tissue sample using amplification oligonucleotides that amplify a fragment comprising at least 700 contiguous nucleotides of SEQ ID NO: 2.
US Pat. No. 10,364,472

METHOD FOR IDENTIFYING WUZHISHAN MINIATURE PIG INBRED LINE BY USING 145 SNPS

1. A method for auxiliarily identifying whether a pig is Wuzhishan miniature pig inbred line, comprising:a) obtaining a DNA sample from the pig;
b) testing a genotype of the pig by hybridizing the DNA sample with each of 145 probes and terminally extending each of the hybridized 145 probes; and
c) identifying the pig to be a candidate for Wuzhishan miniature pig inbred line based on 145 SNP sites if all standards of the following (1) to (145) are satisfied
(1) M1GA0025062 the genotype of SNP site is GG;
(2) DRGA0017627 the genotype of SNP site is GG;
(3) H3GA0056137 the genotype of SNP site is CC;
(4) MARC0039661 the genotype of SNP site is AA;
(5) ASGA0085025 the genotype of SNP site is TT;
(6) ASGA0098570 the genotype of SNP site is GG;
(7) MARC0063358 the genotype of SNP site is AA;
(8) ASGA0085437 the genotype of SNP site is GG;
(9) MARC0096709 the genotype of SNP site is CC;
(10) H3GA0052387 the genotype of SNP site is GG;
(11) ASGA0000264 the genotype of SNP site is TT;
(12) ALGA0000195 the genotype of SNP site is TT;
(13) H3GA0001444 the genotype of SNP site is AA;
(14) ASGA0002293 the genotype of SNP site is CC;
(15) INRA0001752 the genotype of SNP site is GG;
(16) H3GA0001445 the genotype of SNP site is GG;
(17) ALGA0002595 the genotype of SNP site is TT;
(18) ALGA0002600 the genotype of SNP site is GG;
(19) DRGA0000563 the genotype of SNP site is CC;
(20) DRGA0000565 the genotype of SNP site is CC;
(21) INRA0001761 the genotype of SNP site is AA;
(22) MARC0104045 the genotype of SNP site is CC;
(23) ALGA0002601 the genotype of SNP site is CC;
(24) DRGA0000569 the genotype of SNP site is AA;
(25) ALGA0002608 the genotype of SNP site is TT;
(26) DRGA0000568 the genotype of SNP site is CC;
(27) ALGA0002604 the genotype of SNP site is GG;
(28) MARC0048118 the genotype of SNP site is TT;
(29) ASGA0004229 the genotype of SNP site is CC;
(30) MARC0007088 the genotype of SNP site is CC;
(31) MARC0000061 the genotype of SNP site is GG;
(32) MARC0094747 the genotype of SNP site is AA;
(33) MARC0007969 the genotype of SNP site is AA;
(34) ASGA0106092 the genotype of SNP site is CC;
(35) ALGA0119806 the genotype of SNP site is GG;
(36) INRA0003745 the genotype of SNP site is AA;
(37) INRA0003746 the genotype of SNP site is TT;
(38) ALGA0005490 the genotype of SNP site is CC;
(39) H3GA0002538 the genotype of SNP site is CC;
(40) INRA0003749 the genotype of SNP site is CC;
(41) H3GA0002539 the genotype of SNP site is GG;
(42) M1GA0001099 the genotype of SNP site is CC;
(43) MARC0111831 the genotype of SNP site is AA;
(44) ASGA0005566 the genotype of SNP site is CC;
(45) ALGA0007578 the genotype of SNP site is CC;
(46) ASGA0005568 the genotype of SNP site is CC;
(47) INRA0005765 the genotype of SNP site is AA;
(48) MARC0095347 the genotype of SNP site is CC;
(49) MARC0039015 the genotype of SNP site is CC;
(50) DRGA0001892 the genotype of SNP site is GG;
(51) ALGA0007580 the genotype of SNP site is GG;
(52) ALGA0007583 the genotype of SNP site is TT;
(53) MARC0095915 the genotype of SNP site is CC;
(54) ASGA0005571 the genotype of SNP site is AA;
(55) MARC0014134 the genotype of SNP site is AA;
(56) MARC0024233 the genotype of SNP site is AA;
(57) H3GA0003548 the genotype of SNP site is GG;
(58) ALGA0007591 the genotype of SNP site is CC;
(59) MARC0000195 the genotype of SNP site is CC;
(60) ALGA0038697 the genotype of SNP site is CC;
(61) H3GA0020000 the genotype of SNP site is CC;
(62) ALGA0038703 the genotype of SNP site is CC;
(63) H3GA0020002 the genotype of SNP site is GG;
(64) DRGA0007138 the genotype of SNP site is CC;
(65) ASGA0031284 the genotype of SNP site is CC;
(66) ASGA0031285 the genotype of SNP site is AA;
(67) MARC0025042 the genotype of SNP site is GG;
(68) H3GA0020006 the genotype of SNP site is TT;
(69) ALGA0038729 the genotype of SNP site is CC;
(70) ALGA0038731 the genotype of SNP site is GG;
(71) ASGA0031321 the genotype of SNP site is GG;
(72) ASGA0031322 the genotype of SNP site is GG;
(73) ALGA0038747 the genotype of SNP site is AA;
(74) ASGA0033095 the genotype of SNP site is TT;
(75) ALGA0040854 the genotype of SNP site is GG;
(76) ALGA0040856 the genotype of SNP site is AA;
(77) ALGA0040857 the genotype of SNP site is GG;
(78) ASGA0033096 the genotype of SNP site is GG;
(79) INRA0025180 the genotype of SNP site is AA;
(80) ALGA0040859 the genotype of SNP site is CC;
(81) H3GA0021216 the genotype of SNP site is CC;
(82) ASGA0033098 the genotype of SNP site is CC;
(83) H3GA0021221 the genotype of SNP site is CC;
(84) MARC0014540 the genotype of SNP site is CC;
(85) ASGA0033103 the genotype of SNP site is CC;
(86) DIAS0000557 the genotype of SNP site is AA;
(87) ASGA0033116 the genotype of SNP site is AA;
(88) ASGA0036835 the genotype of SNP site is CC;
(89) MARC0031932 the genotype of SNP site is CC;
(90) ASGA0036838 the genotype of SNP site is CC;
(91) H3GA0023523 the genotype of SNP site is GG;
(92) ALGA0045460 the genotype of SNP site is TT;
(93) MARC0005927 the genotype of SNP site is GG;
(94) MARC0005928 the genotype of SNP site is AA;
(95) ASGA0036842 the genotype of SNP site is CC;
(96) ASGA0036846 the genotype of SNP site is CC;
(97) MARC0098637 the genotype of SNP site is TT;
(98) M1GA0011035 the genotype of SNP site is TT;
(99) DRGA0008230 the genotype of SNP site is GG;
(100) ASGA0036855 the genotype of SNP site is CC;
(101) ALGA0097277 the genotype of SNP site is GG;
(102) MARC0080197 the genotype of SNP site is CC;
(103) H3GA0050489 the genotype of SNP site is TT;
(104) ALGA0097281 the genotype of SNP site is TT;
(105) H3GA0050490 the genotype of SNP site is CC;
(106) ALGA0097282 the genotype of SNP site is TT;
(107) ASGA0079089 the genotype of SNP site is CC;
(108) INRA0055354 the genotype of SNP site is GG;
(109) ASGA0079091 the genotype of SNP site is TT;
(110) ASGA0079090 the genotype of SNP site is CC;
(111) H3GA0050491 the genotype of SNP site is AA;
(112) MARC0056017 the genotype of SNP site is TT;
(113) MARC0055759 the genotype of SNP site is AA;
(114) H3GA0050495 the genotype of SNP site is GG;
(115) ALGA0097291 the genotype of SNP site is GG;
(116) ALGA0097290 the genotype of SNP site is GG;
(117) CASI0006683 the genotype of SNP site is GG;
(118) ASGA0079098 the genotype of SNP site is CC;
(119) ALGA0097297 the genotype of SNP site is GG;
(120) H3GA0054426 the genotype of SNP site is TT;
(121) ALGA0098112 the genotype of SNP site is GG;
(122) MARC0089391 the genotype of SNP site is GG;
(123) ASGA0089892 the genotype of SNP site is AA;
(124) ASGA0097792 the genotype of SNP site is CC;
(125) MARC0046857 the genotype of SNP site is GG;
(126) MARC0077194 the genotype of SNP site is AA;
(127) ALGA0108769 the genotype of SNP site is CC;
(128) H3GA0050799 the genotype of SNP site is CC;
(129) ALGA0098120 the genotype of SNP site is CC;
(130) ALGA0098123 the genotype of SNP site is GG;
(131) ALGA0098128 the genotype of SNP site is GG;
(132) ASGA0079719 the genotype of SNP site is CC;
(133) ASGA0079728 the genotype of SNP site is GG;
(134) ASGA0080429 the genotype of SNP site is CC;
(135) MARC0052755 the genotype of SNP site is GG;
(136) ALGA0098918 the genotype of SNP site is GG;
(137) ASGA0080432 the genotype of SNP site is GG;
(138) ALGA0098922 the genotype of SNP site is CC;
(139) INRA0056206 the genotype of SNP site is GG;
(140) INRA0056207 the genotype of SNP site is CC;
(141) ASGA0080435 the genotype of SNP site is CC;
(142) MARC0068495 the genotype of SNP site is GG;
(143) ASGA0080436 the genotype of SNP site is CC;
(144) MARC0003370 the genotype of SNP site is CC;
(145) ASGA0085659 the genotype of SNP site is CC;and, if any standard of the above (1) to (145) is not satisfied, the pig is a candidate for non-Wuzhishan miniature pig inbred line.
US Pat. No. 10,364,473

FAST DIAGNOSIS AND PERSONALIZED TREATMENTS FOR ACNE

THE REGENTS OF THE UNIVER...

1. A method for treating acne in a subject in need thereof, comprising: administering an effective amount of a composition comprising an RT6 strain of P. acnes to the subject.
US Pat. No. 10,364,218

METHOD OF PRODUCING EPSILON-CAPROLACTAM

Toray Industries, Inc., ...

1. A method of producing ?-caprolactam, comprising: step 1 of mixing at least one selected from the group consisting of 3-oxoadipic acid and salts thereof with a catalyst and a solvent in the presence of hydrogen to produce 3-hydroxyadipic acid; and step 2 of reacting the 3-hydroxyadipic acid which is a product of step 1, a salt or carboxylic acid derivative thereof, or a mixture thereof with hydrogen and ammonia.
US Pat. No. 10,363,708

COMPOSITION FOR PREPARING LIGHTWEIGHT TRANSPARENT COMPOSITE, METHOD OF PREPARING COMPOSITE USING THE SAME AND COMPOSITE PREPARED THEREBY

HYUNDAI MOTOR COMPANY, S...

1. A composition for preparing a lightweight transparent composite, comprising:(A) a glass fiber reinforcement having a refractive index of 1.4 to 1.6;
(B) a curable resin having a deviation in refractive index of ?0.005 to +0.005 from the glass fiber reinforcement (A); and
(C) a ruthenium-based catalyst which is a ruthenium metal-based metathesis catalyst comprising at least one selected from the group consisting of molybdenum (Mo), tungsten (W), and osmium (Os).
US Pat. No. 10,364,220

SYNTHESIS OF SUCCINIMIDES AND QUATERNARY AMMONIUM IONS FOR USE IN MAKING MOLECULAR SIEVES

ExxonMobil Chemical Paten...


US Pat. No. 10,363,459

GOLF BALL

SUMITOMO RUBBER INDUSTRIE...

1. A golf ball comprising a spherical core and one or more cover layers disposed outside the spherical core, wherein at least one layer of the cover layers contains:(A) a base resin containing (a-1) an ionomer resin and having a material hardness of 58 or less in Shore D hardness; and
(B) a polyrotaxane having a cyclodextrin with at least a part of hydroxyl groups of the cyclodextrin being modified with a caprolactone chain via —O—C3H6—O— group, a linear molecule piercing through a cyclic structure of the cyclodextrin, and blocking groups located at both terminals of the linear molecule to prevent disassociation of the cyclodextrin.
US Pat. No. 10,364,483

HIGH HARDNESS, HIGH ELASTICITY INTERMETALLIC COMPOUNDS FOR MECHANICAL COMPONENTS

The United States of Amer...

1. A material comprising:54-57 atomic percent nickel (Ni);
0.1 up to and including 27 atomic percent of the sum of one or more elements from the group consisting of zirconium (Zr), hafnium (Hf), rutherfordium (Rf), lanthanum (La), and tantalum (Ta); and
a balance of the material being titanium (Ti) by atomic percent, wherein the material has a lower solvus temperature than that of 60-NITINOL, wherein the material possesses a hardness between 56 and 62 on the Rockwell C (HRC) hardness scale.
US Pat. No. 10,363,206

ORAL CARE COMPOSITIONS

Colgate-Palmolive Company...

1. An oral care composition comprising a calcium abrasive, potassium nitrate (KNO3), and a basic amino acid, in free or salt form, wherein the potassium nitrate is present in an amount of 0.3-0.8% by weight of the composition, wherein the composition is a dentifrice, wherein the calcium abrasive is present in an amount of 30-60% by weight of the composition, wherein the basic amino acid, in free or salt form, is present in an amount of 0.1-20% by weight of the composition, wherein the calcium abrasive is calcium carbonate, and wherein the basic amino acid, in free or salt form, is arginine, in free or salt form.
US Pat. No. 10,363,208

METHODS FOR IMPROVING THE DURABILITY OF COLOR IN ARTIFICIALLY COLORED HAIR

1. A method for artificially coloring hair and inhibiting the coloring from fading, the method comprising:(a) treating hair with a pre-color treatment composition comprising about 0.1 wt. % to about 50 wt. % of one or more divalent metal salts of an inorganic acid and about 0.1 wt. % to about 50 wt. % of one or more monovalent or divalent metal salts of an organic acid; and
(b) treating the hair with a hair coloring composition comprising one or more colorants chosen from oxidative dye precursors, direct dyes, pigments, and mixtures thereof,
wherein the weight ratio of the one or more divalent metal salts of an inorganic acid to the one or more monovalent or divalent metal salts of an organic acid is from about 10:1 to about 1:10, and
all weights being based on the total weight of the pre-color treatment composition.
US Pat. No. 10,363,209

COSMETIC COMPOSITION

Conopco, Inc., Englewood...

1. A cosmetic composition comprising particles dispersed in a cosmetically acceptable carrier,wherein the particles comprise polymer, redox dye and reducing agent;
wherein the cosmetically acceptable carrier is a water and oil emulsion;
wherein the particles are dispersed in the oil phase of the water and oil emulsion;
wherein from 50 to 100% by weight of the particles have a particle size of from 1 to 20 ?m;
wherein the particles comprise polymer in an amount of at least about 80 to 98% by weight of the particles; and
wherein the cosmetic composition comprises the particles in an amount of at least 2% and less than 7%.
US Pat. No. 10,363,721

INTERMEDIATE FILM FOR LAMINATED GLASS AND LAMINATED GLASS

SEKISUI CHEMICAL CO., LTD...

1. An interlayer film for laminated glass comprising:a thermoplastic resin; and
at least one kind of ingredient among a phthalocyanine compound containing copper atom(s) and having a maximum absorption wavelength greater than or equal to 550 nm and less than or equal to 750 nm, a naphthalocyanine compound containing copper atom(s) and having a maximum absorption wavelength greater than or equal to 550 nm and less than or equal to 750 nm, an anthracyanine compound containing copper atom(s) and having a maximum absorption wavelength greater than or equal to 550 nm and less than or equal to 750 nm and an indanthrene compound containing copper atom(s) and having a maximum absorption wavelength greater than or equal to 550 nm and less than or equal to 750 nm,
wherein a content of the at least one kind of ingredient is greater than or equal to 0000001% by weight and less than or equal to 0.05% by weight in 100% by weight of the interlayer film, and
wherein a ratio L?s/Ls of the relative scotopic vision luminance L?s to the relative photopic vision luminance Ls is greater than or equal to 1.0 at the time of preparing laminated glass with two sheets of clear glass in accordance with JIS R3202 (1996).
US Pat. No. 10,363,210

ORAL CARE COMPOSITIONS

Colgate-Palmolive Company...

1. A toothpaste composition comprising:(i) a whitening complex comprising crosslinked polyvinylpyrrolidone complexed with hydrogen peroxide, wherein the whitening complex contains about 10-30% hydrogen peroxide, by weight, and about 5-15% total nitrogen by weight, and
(ii) 25-40% by weight of humectants selected from propylene glycol, glycerin, and combinations thereof;
(iii) 5-15% by weight of polyethylene glycol of average molecular weight 400 to 800 Da;
and wherein the composition comprises 0.5 to 3% of total hydrogen peroxide by weight of the composition, and wherein the composition comprises less than 2% by weight of water; and
(iv) 25-45% by weight of a calcium abrasive.
US Pat. No. 10,363,724

RESIN COMPOSITION AND COMPRESSION-MOLDED ARTICLE OF SAME

Mitsubishi Chemical Corpo...

15. A molded article formed by compression molding the prepreg laminate according to claim 14.
US Pat. No. 10,363,213

IMMUNOGENIC COMPOSITION AGAINST CAMPYLOBACTER JEJUNI

The United States of Amer...

1. A method of inducing an immune response in a mammal against a Campylobacter jejuni strain comprising administering to said mammal an immunogenic composition comprising one or more isolated capsule polysaccharides or polysaccharide polymers derived from Campylobacter jejuni strain HS50; wherein said immunogenic composition does not contain Campylobacter jejuni lipooligosaccharide structures associated with Guillain-Barré Syndrome; wherein said immune response is against a Campylobacter jejuni strain of an HS4 complex selected from the group consisting of Campylobacter jejuni strains HS4, HS13, HS4/13/64, and HS50; wherein the structure of HS4 is [?3)-L-?-D-ido-Hep-(1?4)-?-D-GlcNAc-(1?]n, with non-stoichiometric MeOPN at C-4 of LD-ido-Hep; wherein the structure of HS4/13/64 is [?3)-6d-?-D-ido-Hep-(1?4)-?-D-GIcNAc-(1?]n with non-stoichiometric MeOPN at C-2 and/or C-7 of 6d-ido-Hep; and wherein “n” is 1 to 100.
US Pat. No. 10,363,214

METHOD FOR TREATING ATROPHIC AGE RELATED MACULAR DEGENERATION

Allergan, Inc., Irvine, ...

1. A method for treatment of dry age-related macular degeneration the method comprising the steps of:preparing a biocompatible, sustained release drug delivery system comprising between 5 ?g and 20 ?g of bevacizumab and a polymeric hyaluronic acid vehicle cross-linked or noncross-linked the bevacizumab; and
injecting the drug delivery system into the vitreous of an eye of a patient with dry AMD;
wherein the drug delivery system releases between about 14 ng to about 120 ng of bevacizumab over a 24 hour period for between about 3 months and about 6 months.
US Pat. No. 10,366,799

TRANSPARENT CONDUCTOR, METHOD FOR PREPARING THE SAME AND DISPLAY APPARATUS INCLUDING THE SAME

SAMSUNG SDI CO., LTD., Y...

1. A transparent conductor, comprising:metal nanowires; and
a matrix in which the metal nanowires are embedded,
wherein:
a capping layer is formed on surfaces of the metal nanowires, the capping layer including a sulfur-containing compound, and
the capping layer has a thickness of about 0.025 or less times an average diameter of the metal nanowires.
US Pat. No. 10,363,215

POROUS MICROPARTICLES WITH HIGH LOADING EFFICIENCIES

1. A method of making a double emulsion comprising:preparing by mechanical dispersion a first portion as a high internal phase emulsion, the first portion as the high internal phase emulsion comprising at least one biodegradable polymeric material and at least one cross-linking agent in an organic phase, and further comprising a chemical to prevent Ostwald ripening in an aqueous phase; and
adding drop wise the first portion in a second portion to form a porous microparticle-like composition, the second portion being in an aqueous phase,
wherein the aqueous phase of the first portion is encapsulated in the porous microparticle-like composition,
wherein the biodegradable polymeric material comprises:
a macromer having at least one end group selected from one or more of an acrylate and a methacrylate;
one or more linkages in the macromer, the one or more linkages selected from one or more of an anhydride and an ester,
wherein the biodegradable polymeric material has an octanol-water partition coefficient of between about 2 and about 8,
wherein the biodegradable polymeric material has a viscosity of between about 0.08 cP and about 1000 cP;
wherein the porous microparticle-like composition includes a porous region containing at least one substance selected to be one or more of compatible with a biologic system, and active in a biologic system,
wherein the porous microparticle-like composition has a spherical shape and a cross sectional diameter that is of a generally uniform size, the cross-sectional diameter in a range from between about 20 micrometers and about 1000 micrometers, with a standard deviation that is not more than 50 micrometers when the cross-sectional diameter is greater than 300 micrometers, and
wherein the first portion and the second portion are solvent free.
US Pat. No. 10,364,242

MODULATION OF N-ACYLETHANOLAMINE-HYDROLYSING ACID AMIDASE (NAAA) FOR DISEASE TREATMENT

FONDAZIONE ISTITUTO ITALI...

1. The compound (endo)-3-(4-butylphenoxy)-8-[(3,5-dimethyl-1H-pyrazol-4-yl)sulphonyl]-8-azabicyclo[3.2.1]octane, pharmaceutically acceptable salts thereof, its hydrates, solvates and racemic mixtures.
US Pat. No. 10,365,268

METHODS FOR IDENTIFYING MODULATORS OF MEMBRANE POTENTIALS IN BIPOLAR DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER

PsychNostics, LLC, Ellic...

1. A method of identifying an agent for treatment of attention deficit hyperactivity disorder (ADHD) comprising:combining a first population of human ADHD patient cells comprising cells that express human calcium-activated potassium-channels hSK4, with a test agent suspected of altering human calcium-activated potassium channels hSK4 activity;
obtaining a test ratio of a mean membrane potential of the first population of human ADHD patient cells incubated in vitro in the presence of the test agent suspected of altering human calcium-activated potassium channels hSK4 activity and in the absence of K+, to a mean membrane potential of a second population of the human patient cells incubated in vitro in the absence of the test agent suspected of altering human calcium-activated potassium channels hSK4 activity and presence of K+;
comparing the test ratio to (a) and/or (b):
(a) a control ratio of a mean membrane potential from control human cells known to not have ADHD comprising cells that express human calcium-activated potassium-channels hSK4, incubated in vitro in the presence of a known agent that alters human calcium-activated potassium channels hSK4 activity and in the absence of K+, to a mean membrane potential of the control human cells incubated in vitro in the absence of the known agent that alters human calcium-activated potassium channels hSK4 activity and in the presence of K+,
(b) an ADHD control ratio of a mean membrane potential from ADHD control human cells known to have ADHD comprising cells that express human calcium-activated potassium-channels hSK4, incubated in vitro in the presence of the known agent that alters human calcium-activated potassium channels hSK4 activity and in the absence of K+, to a mean membrane potential of the ADHD control human cells incubated in vitro in the absence of the known agent that alters human calcium-activated potassium channels hSK4 activity and in the presence of K+;
wherein when:
(1) the test ratio is not significantly different from the control ratio of (a),
(2) the test ratio is decreased towards the control ratio of (a) in comparison to the ADHD control ratio of (b), or
(3) the test ratio is decreased in comparison to the ADHD control ratio of (b), the test agent suspected of altering human calcium-activated potassium channels hSK4 activity is identified as the agent for treatment of ADHD and wherein the known agent that alters human calcium-activated potassium channels hSK4 activity is selected from a group consisting of ethanol, amphetamine, ephedrine, cocaine, caffeine, nicotine, methylphenidate, lithium, ?-9-tetrahydrocannibinol, phencyclidine, lysergic acid diethylamide (LSD), mescaline, and combinations thereof.
US Pat. No. 10,363,733

PHOTOSENSITIVE RESIN COMPOSITION, PLANOGRAPHIC PRINTING PLATE PRECURSOR, METHOD FOR PRODUCING PLANOGRAPHIC PRINTING PLATE, AND POLYMER COMPOUND

FUJIFILM CORPORATION, To...

1. A positive type lithographic printing plate precursor comprising:a recording layer which contains a photosensitive resin composition on a support having a hydrophilic surface,
wherein the photosensitive resin composition comprises:
a polymer compound which has an amine bond or a quaternary ammonium salt bond in the main chain, and at least one bond selected from the group consisting of a urea bond, a urethane bond, and a carbonate bond in the main chain and has a sulfonamide group or a phenolic hydroxyl group in the main chain and/or the side chain; and
an infrared absorbing material.
US Pat. No. 10,365,269

SYSTEM AND METHODS FOR DETECTING RIBOSOME INHIBITION

1. A method of measuring ribosome inhibition, the method comprising:providing a genetically-modified cell comprising:
an aminoglycoside-sensitive orthogonal 16S rRNA (O-16S) coding region bearing a mutated anti-Shine-Dalgarno (O-ASD) sequence;
a repressor/operator pair that comprises:
a coding region that encodes a transcriptional regulator and having an orthogonal SD (O-SD) sequence complementary to the 16S rRNA O-ASD sequence; and
an operator sequence repressable by the transcriptional regulator; and
a polynucleotide encoding a detectable reporter operably linked to the operator sequence repressable by the transcriptional regulator;
contacting the cell with a test compound; and
detecting a signal produced by the reporter, wherein intensity of the signal indicates a dose dependent degree of ribosome inhibition.
US Pat. No. 10,365,271

LIGHT HARVESTING MULTICHROMOPHORE COMPOSITIONS AND METHODS OF USING THE SAME

The Regents of the Univer...

1. An aqueous composition comprising an aggregate of light harvesting multichromophore conjugated polymers in an aqueous solution that are configured upon excitation to transfer energy to, and amplify the emission from, an acceptor signaling chromophore in energy-receiving proximity therewith in the aqueous solution, wherein the light harvesting multichromophore conjugated polymers comprise water soluble groups and are linked to a sensor biomolecule that specifically binds a target.
US Pat. No. 10,363,225

NON-BLEEDING BIOACTIVE NATURAL PIGMENTS WHICH PREVENT COLOR AND DUST EXPLOSIONS, METHOD OF PREPARATION THEREOF

1. A Non-bleeding curcumin (NBC) consisting of curcumin and a coating of polymer, whereinthe polymer is selected from the group consisting of hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyvinyl alcohol and mixtures thereof;
the NBC contains concentration of curcuminoids not less than 90% (w/w) and up to 95% (w/w) measured by HPLC, which is substantially equivalent to standard curcumin with 95% purity;
the NBC having the particle size distribution in the range of 180 to 2000 microns;
the NBC retains radical scavenging property, biological activity, flavor, and color of said standard curcumin;
and the polymer prevents color leakage, bleeding, staining or dusting during industrial processing of said curcumin.
US Pat. No. 10,363,229

METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER

1. A method for treating a metastatic cancer in a subject having the metastatic cancer comprising administering to the subject a therapeutically effective amount of methyl sulfone, thereby treating the cancer, wherein the therapeutically effective amount comprises a solution of methyl sulfone in the range of 0.2 to 0.6 mg methyl sulfone/ml solvent, or 1.0 to 5.0 mg methyl sulfone/ml solvent, and wherein administration of the methyl sulfone to the subject induces cells of the cancer to revert to a normal cellular phenotype from a cancer cell phenotype.
US Pat. No. 10,365,279

ASSAY SYSTEM FOR THE ASSESSMENT OF ONCOGENICITY, TUMOR PROGRESSION, AND TREATMENT EFFICACY

Berg LLC, Framingham, MA...

1. A method for diagnosing and treating cancer in a subject, comprising:(i) detecting in a tissue sample obtained from a suspected lesion of abnormal growth from the subject a decrease in total cellular protein level of Cytochrome C and proteins implicated in apoptosis comprising Bax, p53, Bid, and Caspase-3, based on comparison with a baseline value of the proteins;
(ii) detecting in the tissue sample an increase in total cellular protein level of two or more proteins implicated in angiogenesis, wherein the proteins are selected from the group consisting of VEGF, HIF-1?, and bFGF, based on comparison with a baseline value of the proteins;
(iii) determining that the tissue sample is cancerous, exhibits angiogenesis indicative of an aggressive cancer, and exhibits significant apoptotic resistance to chemotherapy treatment; and
(iv) administering a non-chemotherapy or anti-angiogenic cancer treatment to the subject based on the determination in step (iii).
US Pat. No. 10,364,512

MULTIFILAMENT AND BRAID

TOYOBO CO., LTD., Osaka-...

10. A braid comprising a multifilament comprising 5 or more monofilaments, whereinthe braid shows 1000 times or more in number of reciprocating abrasions at break in an abrasion resistance test measured at a load of 5 cN/dtex in accordance with JIS L-1095, and
the multifilament contains polyethylene having an intrinsic viscosity [?] of 5.0 dL/g or more and 40.0 dL/g or less and substantially including ethylene as a repeating unit.
US Pat. No. 10,364,514

FLUOROPOLYMER FIBRE

SOLVAY SA, Brussels (BE)...

1. A process for manufacturing one or more fluoropolymer fibres, said process comprising:contacting a liquid composition (C1) comprising:
at least one fluoropolymer comprising at least one hydroxyl end group [polymer (FOH)], and
a liquid medium comprising at least one organic solvent (S);with at least one metal compound (M) of formula (I):X4?mAYm  (I)
wherein X is a hydrocarbon group, optionally comprising one or more functional groups, m is an integer from 1 to 4, A is a metal selected from the group consisting of Si, Ti and Zr, and Y is a hydrolysable group selected from the group consisting of an alkoxy group, an acyloxy group and a hydroxyl group, thereby providing a liquid composition (C2);
submitting composition (C2) to at least partial hydrolysis and/or polycondensation, thereby providing a liquid composition (C3) comprising at least one fluoropolymer hybrid organic/inorganic composite;
processing composition (C3) by electrospinning, thereby providing one or more fluoropolymer fibres;
drying the fluoropolymer fibre(s), thereby providing one or more dried fluoropolymer fibres; and
optionally, submitting to compression the dried fluoropolymer fibre(s) at a temperature comprised between 50° C. and 300° C., thereby providing compressed fluoropolymer fibres.
US Pat. No. 10,366,568

LOTTERY GAME PROVIDING A CHANCE TO WIN A JACKPOT AT A REDUCED COST TO THE PLAYER, WITH AN INCREASED REVENUE TO THE OPERATOR AND TICKET RETAILER

1. A method of playing a game of chance comprising:providing a Player an entry recorded on a printed ticket to said game of chance from a Ticket Retailer, said game of chance comprising a prize structure, said prize structure comprising a jackpot and a plurality of lesser prizes, wherein said entry provides a chance to win said jackpot and a reduced subset or no subset of said plurality of lesser prizes,
wherein said entry is printed on said ticket by a computer system configured to generate the entry based on random generation of the entry or user input and to print the entry on the printed ticket,
and wherein the entry is purchased at a reduced cost as compared to an entry with a chance to win all available prizes in the game of chance.
US Pat. No. 10,363,244

COMPOSITIONS COMPRISING METFORMIN AND A GLUCOKINASE ACTIVATOR

vTv Therapeutics LLC, Hi...

1. A pharmaceutical composition comprising:(a) {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid or a pharmaceutically acceptable salt thereof,
(b) less than 1000 mg of metformin, and
(c) at least one pharmaceutically acceptable carrier, excipient, diluent, or a mixture thereof.
US Pat. No. 10,363,245

METHODS FOR TREATING CNS LESIONS

THE BOARD OF REGENTS OF T...

1. A method of treating a brain lesion in a subject diagnosed with multiple sclerosis (MS) comprising orally administering a carbonic anhydrase inhibitor to the subject in an effective amount to increase cerebral perfusion.
US Pat. No. 10,364,271

IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, IN PARTICULAR CHRONIC LYMPHOID LEUKEMIA (CLL)

Immatics Biotechnologies ...

1. A method of eliciting an immune response in a patient who has cancer, comprising administering to said patient a population of activated T cells that selectively recognize cells, which present a peptide consisting of the amino acid sequence SEQ ID NO: 63, wherein said cancer is selected from the group consisting of chronic lymphoid leukemia (CLL), acute myelogenous leukemia (AML), adrenal gland adrenal cortical adenoma, bone giant cell tumor of bone, bone non-ossifying fibroma, breast carcinoma, colon adenocarcinoma, non-Hodgkin's lymphoma, endometrium adenocarcinoma endometrioid, kidney angiomyolipoma, kidney carcinoma, kidney oncocytoma, liver focal nodular hyperplasia, liver hepatocellular carcinoma, lymph node Hodgkin's disease, lymph node papillary carcinoma of thyroid, medullary carcinoma of thyroid origin, metastatic adenocarcinoma of stomach, neurofibroma, ovary thecoma fibroma, pancreas adenocarcinoma, pancreas microcystic adenoma, parathyroid gland adenoma, rectum adenocarcinoma, skin squamous cell carcinoma, spleen chronic myeloid leukemia, stomach gastrointestinal stromal tumor (GIST), thyroid gland nodular hyperplasia, thyroid gland papillary carcinoma, and uterine cervix squamous cell carcinoma.
US Pat. No. 10,364,275

METHODS FOR TREATING INFLAMMATORY RESPONSES OR DISEASES CAUSED BY INFLAMMATION USING APOA-I BINDING PROTEIN (APOA1BP)

The Regents of the Univer...

1. A method for treating, reversing, preventing or down-regulating an inflammatory response associated with hyperlipidemia, comprising administering to an individual an effective amount of: an ApoA-I Binding Protein (APOA1BP, AIBP, or AI-BP) polypeptide or a pharmaceutical composition comprising an ApoA-I Binding Protein (APOA1BP, AIBP, or AI-BP) polypeptide,wherein the ApoA-I Binding Protein (APOA1BP, AIBP, or AI-BP) polypeptide comprises a sequence as set forth in SEQ ID NO:43, SEQ ID NO:44 or SEQ ID NO:45.
US Pat. No. 10,362,741

TOMATO FRUIT HAVING INCREASED FIRMNESS

Syngenta Participations A...

1. A Solanum lycopersicum tomato fruit with significantly increased fruit firmness at the harvesting stage comprising at least one genetic element in the cultivated Solanum lycopersicum tomato plant producing said tomato fruit, wherein said firmness is measured on the inner pericarp and is from between 1.2 to 2.0 times greater than that of fruit from a control Solanum lycopersicum tomato plant which does not have the said at least one genetic element, wherein said genetic element is identical to a genetic element of Solanum lycopersicum QTL-NIL 301 deposited with NCIMB under accession number 41662, and wherein the said genetic element of QTL-NIL 301 is linked to at least one DNA marker in the cultivated Solanum lycopersicum tomato plant, said at least one DNA marker selected from:a) NT3853, which can be detected by a forward primer of SEQ ID NO: 1 and a reverse primer of SEQ ID NO: 2;
b) NT3907, which can be detected by a forward primer of SEQ ID NO: 3 and a reverse primer of SEQ ID NO: 4;
c) TG14, which can be detected by a forward primer of SEQ ID NO: 5 and a reverse primer of SEQ ID NO: 6;
d) HOX7A, which can be detected by a forward primer of SEQ ID NO: 7 and a reverse primer of SEQ ID NO: 8;
e) CT277, which can be detected by a forward primer of SEQ ID NO: 9 and a reverse primer of SEQ ID NO: 10;
f) Lm0127, which can be detected by a forward primer of SEQ ID NO: 11 and a reverse primer of SEQ ID NO: 12;
g) Lm1650, which can be detected by a forward primer of SEQ ID NO: 13 and a reverse primer of SEQ ID NO: 14;
h) LE5100, which can be detected by a forward primer of SEQ ID NO: 15 and a reverse primer of SEQ ID NO: 16;
i) LE5200, which can be detected by a forward primer of SEQ ID NO: 17 and a reverse primer of SEQ ID NO:18;
j) HB2600, which can be detected by a forward primer of SEQ ID NO: 19 and a reverse primer of SEQ ID NO: 20; and
k) TG353, which can be detected by a forward primer of SEQ ID NO: 21 and a reverse primer of SEQ ID NO: 22.
US Pat. No. 10,362,743

LETTUCE VARIETY 41-673 RZ

RIJK ZWAAN ZAADTEELT EN Z...

1. A seed of lettuce variety 41-673 RZ, a sample of seed of said variety having been deposited under NCIMB accession No. 42613.
US Pat. No. 10,364,280

POLYPEPTIDE

AFFIBODY AB, Solna (SE)

wherein, independently from each other,X4 is selected from I, M, V and W;
X6 is selected from T and V;
X10 is selected from M and V;
X11 is selected from D and Q;
X16 is selected from N and T;
X17 is selected from A and S;
X18 is selected from G, R and W;
X20 is selected from K and R;
X25 is selected from D, N and W; and
X26 is selected from K and S;andii) an amino acid sequence which has at least 96% identity to the sequence defined in i).
US Pat. No. 10,362,745

WHEAT CULTIVAR 01071782

Monsanto Technology LLC, ...

1. A plant of wheat cultivar 01071782, wherein a sample of seed of said cultivar has been deposited under ATCC Accession No. PTA-125540.
US Pat. No. 10,364,281

IMMUNOTHERAPY AGAINST MELANOMA AND OTHER CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. A method for treating a patient who has cancer comprising administering to the patient a population of activated T cells that selectively recognize cancer cells that present a peptide consisting of the amino acid sequence of VLKADVVLL (SEQ ID NO: 42),wherein said cancer is selected from the group consisting of melanoma, acute myelogenous leukemia, breast cancer, bile duct cancer, brain cancer, chronic lymphocytic leukemia, colorectal carcinoma, esophageal cancer, gallbladder cancer, gastric cancer, hepatocellular cancer, non-Hodgkin lymphoma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer, small cell lung cancer, urinary bladder cancer, and uterine cancer.
US Pat. No. 10,364,282

PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. A method of treating a patient who has a cancer overexpressing KRT5 polypeptide comprising the amino acid sequence of SEQ ID NO: 2, comprising administering to said patient a composition comprising a population of activated T cells that kill the cancer cells,wherein the activated T cells are cytotoxic T cells produced by contacting T cells with an antigen presenting cell that presents a peptide consisting of the amino acid sequence of SEQ ID NO: 2 in a complex with an MHC class I molecule on the surface of the antigen presenting cell in vitro, for a period of time sufficient to activate said T cell,
wherein said cancer is selected from the group consisting of esophageal cancer, lung cancer, urinary bladder cancer, head and neck cancer, and gastric cancer.
US Pat. No. 10,362,747

WHEAT CULTIVAR 01071585

Monsanto Technology LLC, ...

1. A plant of wheat cultivar 01071585, wherein a sample of seed of said cultivar has been deposited under ATCC Accession No.PTA-125547.
US Pat. No. 10,362,749

WHEAT CULTIVAR 01071780

Monsanto Technology LLC, ...

1. A plant of wheat cultivar 01071780, wherein a sample of seed of said cultivar has been deposited under ATCC Accession No. PTA-125541.
US Pat. No. 10,364,285

ANTIBODIES FOR THE TREATMENT OF SYNUCLEINOPATHY

1. A monoclonal antibody which specifically binds to human alpha-synuclein and comprises:(a) a Heavy Chain CDR1 comprising the amino acid sequence of SEQ ID NO:1;
(b) a Heavy Chain CDR2 comprising the amino acid sequence of SEQ ID NO:34;
(c) a Heavy Chain CDR3 comprising the amino acid sequence of SEQ ID NO:3;
(d) a Light Chain CDR1 comprising the amino acid sequence of SEQ ID NO:4;
(e) a Light Chain CDR2 comprising the amino acid sequence of SEQ ID NO:5; and
(f) a Light Chain CDR3 comprising the amino acid sequence of SEQ ID NO:6.
US Pat. No. 10,362,751

WHEAT CULTIVAR 01071571

Monsanto Technology LLC, ...

1. A plant of wheat cultivar 01071571, wherein a sample of seed of said cultivar has been deposited under ATCC Accession No. PTA-125544.
US Pat. No. 10,365,568

CONTROL METHOD OF MOVABLE BODY, EXPOSURE METHOD, DEVICE MANUFACTURING METHOD, MOVABLE BODY APPARATUS, AND EXPOSURE APPARATUS

NIKON CORPORATION, Tokyo...

1. A beam irradiation apparatus, comprising:an irradiation system from which a processing beam is irradiated to an object to process the object with the processing beam;
a movable body that is movable relative to the irradiation system within a two-dimensional plane including a first direction and a second direction intersecting the first direction;
a mark detection system arranged separate from the irradiation system, from which a measurement beam is irradiated to the object placed on the movable body to detect marks of the object, the mark detection system having an optical member and an irradiation position of the measurement beam being changed in the first direction using the optical member; and
a controller,
wherein:
the controller controls movement of the movable body,
the mark detection system detects a first mark of the marks while moving the movable body in the first direction and changing the irradiation position of the measurement beam in the first direction,
the mark detection system detects a second mark of the marks while moving the movable body in the first direction and changing the irradiation position of the measurement beam in the first direction,
the controller controls a position of the movable body in the second direction during a time period between the detection of the first mark and the detection of the second mark, and
the controller controls the movement of the movable body to adjust a positional relation between the object on the movable body and the processing beam, based on results of the detection of the first mark and the detection of the second mark.
US Pat. No. 10,362,752

WHEAT CULTIVAR 01071581

Monsanto Technology LLC, ...

1. A plant of wheat cultivar 01071581, wherein a sample of seed of said cultivar has been deposited under ATCC Accession No. PTA-125543.
US Pat. No. 10,364,288

ANTI-GPIIB/IIIA ANTIBODIES OR USES THEREOF

Biogen MA Inc., Cambridg...

1. An antibody or antigen-binding fragment thereof that binds to glycoprotein IIb/IIIa (GPIIb/IIIa), wherein the antibody or the antigen-binding fragment thereof comprises a heavy chain variable region (VH) comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:the VH CDR1 comprises the amino acid sequence AYAMS (SEQ ID NO:31);
the VH CDR2 comprises the amino acid sequence SISSGGTTYYPDSVKR (SEQ ID NO:32); and
the VH CDR3 comprises the amino acid sequence GGDYGYALDY (SEQ ID NO:33); and
wherein the antibody or the antigen-binding fragment thereof comprises a light chain variable region (VL) comprising VL CDR1, VL CDR2, and VL CDR3, wherein:
the VL CDR1 comprises the amino acid sequence RASSSVNYMY (SEQ ID NO:34);
the VL CDR2 comprises the amino acid sequence YTSNLAP (SEQ ID NO:35); and
the VL CDR3 comprises the amino acid sequence QQFSSSPWT (SEQ ID NO:36).
US Pat. No. 10,362,753

PLANTS AND SEEDS OF HYBRID CORN VARIETY CH811229

Monsanto Technology LLC, ...

1. A seed of hybrid corn variety CH811229, produced by crossing a first plant of variety CV342520 with a second plant of variety CV655219, wherein representative seeds of said varieties CV342520 and CV655219 are deposited under ATCC Accession Nos. PTA-121222 and PTA-125222, respectively.
US Pat. No. 10,362,754

PLANTS AND SEEDS OF HYBRID CORN VARIETY CH267399

Monsanto Technology LLC, ...

1. A seed of hybrid corn variety CH267399, produced by crossing a first plant of variety CV602186 with a second plant of variety CV132428, wherein representative seeds of said varieties CV602186 and CV132428 are deposited under ATCC Accession Nos. PTA-125251 and PTA-121108, respectively.
US Pat. No. 10,364,292

MONOVALENT BLOOD BRAIN BARRIER SHUTTLE MODULES

Hoffmann-La Roche Inc., ...

1. A blood brain barrier shuttle module comprising a brain effector entity, optionally a linker and exactly one (monovalent) binding entity which binds to transferrin receptor (TfR), wherein the linker if present couples the effector entity to the monovalent binding entity, wherein the monovalent binding entity comprises an anti-TfR antibody or fragment thereof comprising (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 109; (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 110; (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 112; (d) a HVR-L1 comprising the amino acid sequence of SEQ ID NO: 113; (e) a HVR-L2 comprising the amino acid sequence of SEQ ID NO: 114; and (f) a HVR-L3 comprising the amino acid sequence of SEQ ID NO: 115.
US Pat. No. 10,362,758

SOYBEAN CULTIVAR 64272401

Monsanto Technology LLC, ...

1. A plant of soybean cultivar 64272401, representative seed of said soybean cultivar having been deposited under ATCC Accession No. PTA-125270.
US Pat. No. 10,364,300

METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW

Bridgestone Corporation, ...

1. A method for preparing a coupled polymer, the method comprising the steps of:(i) polymerizing conjugated diene monomer to form a reactive polymer, where said step of polymerizing employs either a coordination catalyst or an anionic initiator, and
(ii) reacting the reactive polymer with a carboxylic or thiocarboxylic ester containing a nitro group, where the carboxylic or thiocarboxylic ester containing a nitro group includes a single nitro group.
US Pat. No. 10,362,768

EXTRUDED ANIMAL LITTERS

1. An animal litter comprising from about 30 to about 70% of one or more clays and from about 70 to about 30% of one or more starches, wherein the starches have an expanded cellular structure.
US Pat. No. 10,363,536

GELLED COMPOSITION FOR AN ORGANIC MONOLITHIC GEL, USES THEREOF AND PROCESS FOR PREPARING SAME

HUTCHINSON, Paris (FR)

1. A gelled carbon-based composition forming an organic polymeric monolithic gel which is capable of forming an aerogel by drying and a porous carbon monolith by pyrolysis of said aerogel,wherein the composition comprises a resin derived at least partly from:
a first unsubstituted polyhydroxybenzene,
a premix comprising at least a second unsubstituted polyhydroxybenzene and at least one substituted polyhydroxybenzene substituted with one or more alkyl groups, and
formaldehyde(s),
wherein the composition comprises a water-soluble cationic polyelectrolyte.
US Pat. No. 10,363,284

?-HAIRPIN PEPTIDOMIMETICS

POLYPHOR AG, Allschwil (...

1. A method for providing CXCR4 antagonizing activity, and/or anti inflammatory activity and/or stem cell mobilizing activity, for providing CXCR4 antagonizing activity, and/or stem cell mobilizing activity for slowing or halting the viral progression in an HIV infected patient; for treating a cancer or an immunological disease that is mediated by or results from CXCR4 receptor activity; for treating immunosuppression; for accompanying the apheresis collection of peripheral blood stem cells; or for inducing the mobilization of stem cells to regulate tissue repair, said method comprising:administering an effective amount of a compound of the general formula cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Xaa6-DPro7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Xaa13-Xaa14-Xaa15-Pro16-),
comprising a disulfide bond between Cys4 and Cys11, and pharmaceutically acceptable salts thereof,
wherein
Xaa3 is Tyr; Tyr(Me); or Tyr(CF3),
Tyr(Me) is (2S)-2-amino-(4-methoxyphenyl)-3-propionic acid,
Tyr(CF3) is (2S)-2-amino-(4-trifluoromethoxyphenyl)-3-propionic acid,
Xaa6 is Ala; or Acc
Acc is 1-aminocyclopropane-carboxylic acid,
Xaa8 is Orn(iPr),
Orn(iPr) is (2S)—N?-isopropyl-2,5-diaminopentanoic acid,
Xaa13 is Gln; or Glu,
Xaa14 is Lys(iPr),
Lys(iPr) is (2S)—N?-isopropyl-2,6-diaminohexanoic acid,
Xaa15 is DPro; or DLys(iPr),
DLys(iPr) is (2R)—N?-isopropyl-2,6-diaminohexanoic acid,
with the proviso that if Xaa6 is Ala, then Xaa15 is DLys(iPr).
US Pat. No. 10,364,308

THERMOPLASTIC POLYOLEFIN COMPOSITIONS

ExxonMobil Chemical Paten...

1. A thermoplastic polyolefin composition comprising:a polypropylene having a melting point temperature (Tm) of greater than 130° C. and a melt flow rate (230° C./2.16 kg) within the range from 10 g/10 min to 80 g/10 min;
an ethylene-propylene copolymer comprising within the range from 40 wt % to 80 wt % ethylene derived units and having a Mooney Viscosity (1+4, 125° C.) of greater than about 20 Mooney units, a Mw/Mn within the range from 1.8 to 4.0, and a weight average molecular weight (Mw) within a range of from 50,000 g/mole to 300,000 g/mole; and
a propylene-based elastomer having within the range from 5 to 25 wt % ethylene derived units and having a melting point temperature (Tm) of less than 110° C. and a Mw/Mn within the range from 2.0 to 4.0,
wherein the room temperature notch impact of the thermoplastic polyolefin composition is at least twenty times greater than the room temperature notch impact of a composition without the propylene-based elastomer.
US Pat. No. 10,363,286

PEPTIDE INHIBITION OF CCR3-MEDIATED DISEASES OR CONDITIONS

The Board of Trustees of ...

1. A C—C chemokine receptor (CCR3) peptide analog comprising the amino acid sequence LLNLAISDLLFLVTLPFWIHY (SEQ ID NO:17) or LLFLVTLPFWIHYVRGHNWVFGH (SEQ ID NO:18), wherein said peptide analog is PEGylated and is up to 50 amino acid residues in length.
US Pat. No. 10,364,311

HFO-1234ZE COPOLYMERS

THE CHEMOURS COMPANY FC, ...

1. A copolymer comprising 1 to 40 mol % 1,3,3,3 tetrafluoropropene, 15 to 60 mol % vinylidene fluoride, 5 to 25 mol % tetrafluoroethyene, and 15 to 40 mol % perfluoro(alkyl vinyl ether), to total 100 mol %.
US Pat. No. 10,363,290

BUTYRYLCHOLINESTERASE ZWITTERIONIC POLYMER CONJUGATES

KODIAK SCIENCES INC., Pa...

1. A fusion protein comprising: a butyrylcholinesterase enzyme or carboxy terminal truncation fragment thereof and an immunoglobulin (Ig) domain or fragment thereof, wherein a linker is positioned between and connecting the butyrylcholinesterase enzyme or fragment thereof and the Ig domain of fragment, wherein the Ig domain or fragment thereof comprises substitutions L234A, L235E, and G237A per EU numbering which corresponds to substitutions L14A, L15E, and G17A as numbered within SEQ ID NO: 8, wherein the linker is selected from the group consisting of at least one of Q, GOG, GGGGS (SEQ ID NO: 22), GGGS (SEQ ID NO: 23), GGGES (SEQ II) NO: 24), GGGSGGGSGGGS (SEQ ID NO: 21), and GGSGGGSGGGS (SEQ ID NO: 25).
US Pat. No. 10,363,546

MULTILAYER POLYMERIC MEMBRANE

Liso Plastics LLC, Charl...

1. A multilayer sorbent polymeric membrane comprising at least one layer comprising: a matrix polymer, sorbent materials of about 100 wt. % or less, and a plurality of interconnecting pores having an average pore size of about 0.1 nm or greater,wherein the matrix polymer is a film-forming thermoplastic polymer selected from the group consisting of petroleum-based polymers, bio-based polymers, biodegradable polymers, and combinations thereof;
wherein the sorbent materials present in the membrane retain their initial sorbability and/or their initial porosity of about 100% or less; and
wherein the membrane has a porosity of about 85% or less and a Gurley air permeability of about 1 sec/100 cc or greater.
US Pat. No. 10,363,293

VACCINE COMPOSITION

Turnstone Limited Partner...

1. A method for treating a patient having a cancer, said method comprising:a) a first virus, said first virus comprising a nucleic acid that is capable of expressing a MAGEA3 protein, said MAGEA3 protein comprising an amino acid sequence that is at least 70% identical to SEQ ID NO: 1, and includes at least one MAGEA3 tumor-associated epitope selected from the group consisting of: FLWGPRALV (SEQ ID NO: 27), KVAELVHFL (SEQ ID NO: 28), EGDCAPEEK (SEQ ID NO: 35), KKLLTQHFVQENYLEY (SEQ ID NO: 36), and RKVAELVHFLLLKYR (SEQ ID NO: 37), wherein said MAGEA3 protein is capable of inducing an immune response in a patient in a heterologous prime-boost format, and
b) a second virus, said second virus being a Maraba MG1 virus comprising a nucleic acid that is capable of expressing a MAGEA3 protein, said MAGEA3 protein comprising an amino acid sequence that is at least 70% identical to SEQ ID NO: 1, and includes at least one MAGEA3 tumor-associated epitope selected from the group consisting of: FLWGPRALV (SEQ ID NO: 27), KVAELVHFL (SEQ ID NO: 28), EGDCAPEEK (SEQ ID NO: 35), KKLLTQHFVQENYLEY (SEQ ID NO: 36), and RKVAELVHFLLLKYR (SEQ ID NO: 37), wherein said Maraba MG1 virus is formulated for use in providing a therapeutic oncolytic effect in said patient; wherein:
said first virus is immunologically distinct from said second virus;
said first virus is a priming virus and administered before said second virus; and wherein
said second virus is a boost virus and is administered at least twice after administration of said priming virus.
US Pat. No. 10,366,878

SELECTIVE DEPOSITION THROUGH FORMATION OF SELF-ASSEMBLED MONOLAYERS

Applied Materials, Inc., ...

1. A processing method comprising:providing a substrate with a first surface and a second surface;
exposing the substrate to a SAM precursor to form a self-assembled monolayer on the second surface;
depositing a film on the first surface selectively over the second surface; and
removing the self-assembled monolayer from the second surface,
wherein the SAM precursor comprises a composition with a head group that adsorbs to the second surface and a tail group that associates through van der Waals interaction, and
wherein unreacted head groups of chemisorbed SAM precursors undergo ligand exchange with a treatment co-reactant and subsequently exchanged head groups of the SAM precursors react with each other via a condensation reaction to yield crosslinking between the chemisorbed SAM precursors.
US Pat. No. 10,364,318

ENGINEERED STRAIN OF ESCHERICHIA COLI FOR PRODUCTION OF POLY-R-3-HYDROXYALKANOATE POLYMERS WITH DEFINED MONOMER UNIT COMPOSITION AND METHODS BASED THEREON

The Research Foundation f...

1. A system for producing a prescribed unit size azido-poly(3-hydroxyalkanoate) (azido-PHA) polymer comprising a recombinant bacterium, wherein the bacterium:a. metabolizes short to long chain fatty acids without induction, and
b. expresses an (R)-specific enoyl-CoA hydratase and a PHA synthase, wherein the bacterium is fed a fatty acid substrate, wherein the fatty acid substrate is a ?-azido-fatty acid substrate, the ?-azido-fatty acid comprising a terminal azide, and the ?-azido-fatty acid being of equal carbon length to the prescribed unit size of the azido-PHA polymer to be produced.
US Pat. No. 10,364,321

BATCH PROCESS FOR MAKING POLYBUTYLENE TEREPHTHALATE

SABIC GLOBAL TECHNOLOGIES...

1. A batch process for preparing polybutylene terephthalate (PBT), comprising:heating at approximately 245-260° C. and 1 atmosphere of pressure a solid PBT oligomer having an intrinsic viscosity (IV) of 0.1 to 0.2 dL/g and a carboxylic acid end group concentration [CEG] of greater than 100 to 180 mmol/kg until the PBT melts and becomes homogeneous to form melted homogeneous PBT oligomer; wherein the PBT oligomer contains 30 to 150 ppm tetra(C1-C8 alkyl) titanate catalyst;
adding 30 to 150 ppm tetra(C1-C8 alkyl) titanate catalyst; and
polycondensing the melted homogeneous PBT oligomer by reducing the pressure to approximately 0.1 to 4 mm Hg, and maintaining the temperature at approximately 245-260° C. to provide PBT having an IV of between 0.55 and 1.20 dL/g.
US Pat. No. 10,364,323

METHOD FOR PRODUCING POLYETHER CARBONATE POLYOLS

Covestro Deutschland AG, ...

1. A process for preparing polyether carbonate polyols comprising adding alkylene oxides and carbon dioxide onto carboxylic acids in the presence of a double metal cyanide (DMC) catalyst, wherein one or more carboxylic acids are metered into the reactor continuously during the reaction, in which(i) said carboxylic acid is at least difunctional and has a pKa of not less than 1.5,
(ii) the addition of said one or more carboxylic acids is effected such that at any point in time in the process the molar concentration of unconverted carboxylic acid in the reaction mixture does not exceed a value of 0.001 mol/g multiplied by the mass of the catalyst employed per liter of reaction mixture reported in grams, and
(iii) any two carboxylic acid groups present in the same molecule are separated from one another at least by a carbon atom.

US Pat. No. 10,368,293

UTILIZING EXPLICIT CONGESTION NOTIFICATION FOR NETWORK SELECTION

1. A user equipment, comprising:a processor; and
a memory that stores executable instructions that, when executed by the processor, facilitate performance of operations, comprising:
determining that a first device and a second device are available to serve the user equipment, wherein the first device corresponds to a first network and communicates according to a first network protocol and the second device corresponds to a second network and communicates according to a second network protocol that differs from the first network protocol;
determining that an application, executed by the user equipment, is configured to request communication of application data;
receiving explicit congestion notification data comprising a first bit indicative of a first explicit congestion notification of the first network and a second bit indicative of a second explicit congestion notification of the second network; and
based on the explicit congestion notification data, determining, from among the first network and the second network, a selected network that is selected to communicate the application data.

US Pat. No. 10,368,291

CONTROLLING USE OF VEHICULAR WI-FI HOTSPOTS BY A HANDHELD WIRELESS DEVICE

GM Global Technology Oper...

1. A method of controlling use of vehicular Wi-Fi hotspots by a handheld wireless device, comprising the steps of:(a) detecting that the handheld wireless device is communicating via a Wi-Fi hotspot;
(b) determining at the handheld wireless device that the Wi-Fi hotspot is provided by a vehicle, including:
(b1) comparing a received identifier of the Wi-Fi hotspot with content of a database containing vehicular Wi-Fi identifiers; and
(b2) identifying the received identifier in the database containing vehicular Wi-Fi identifiers; and
(c) enabling one or more default prohibitions against transmitting low-priority data from the handheld wireless device to a remote server via the Wi-Fi hotspot provided by the vehicle and a cellular wireless carrier system to which the vehicle is connected while the handheld wireless device communicates with the Wi-Fi hotspot provided by the vehicle.

US Pat. No. 10,368,290

COOPERATIVE COMMUNICATION LINK MAPPING AND CLASSIFICATION

SIKORSKY AIRCRAFT CORPORA...

1. A method of cooperative communication link mapping and classification, the method comprising:receiving location data defining a position of a communication node;
monitoring signal data of a communication link at the communication node with respect to a second communication node;
identifying characteristics of the signal data;
applying a location stamp of the position to the characteristics of the signal data;
classifying the communication link based on the characteristics of the signal data; and
populating a map classifying the communication link at the position indicated by the location stamp, wherein a time stamp is applied for each update of the map.

US Pat. No. 10,368,289

APPARATUS AND METHOD FOR COMMUNICATIONS MANAGEMENT

BAE Systems plc, London ...

1. Apparatus for generating a connectivity map in respect of a communications system of a moving platform, said communications system comprising at least one platform application and being configured to effect wireless data communication between said platform and another node by means of one of a plurality of supported communications links in accordance with a communications plan, wherein said apparatus is configured to: identify a message or set of messages required to be transmitted from or received by said moving platform; and generate a connectivity map comprising a plurality of connectivity metrics by, for each of a plurality of different specified attitudes or orientations derived from one or more predicted trajectories of said moving platform: identifying available transmitters for wireless transmission of said message or set of messages and/or identify available receivers for wireless reception of said message or set of messages; for each identified transmitter, determining a transmitter metric and/or for each identified receiver, determining a receiver metric; defining a connectivity metric, based on said transmitter metrics and/or receiver metrics for said respective specified attitude or orientation, said connectivity metric being representative of a quality of a respective associated communications link for effecting transmission or reception by said platform of said message or set of messages in respect of said respective specified attitude or orientation of said moving platform; anda management system for a moving platform comprising a plurality of systems and at least one platform application, a dynamic route planner configured to generate a new heading plan in respect of said moving platform, a platform application and being configured to effect wireless data communication supported communications links in accordance with a communications plan, wherein said dynamic route planner or said dynamic obstacle avoidance planner is configured to use said connectivity map to generate a route plan or heading plan including an attitude/orientation of said moving platform corresponding to a selected connectivity metric.

US Pat. No. 10,368,280

METHOD FOR CONTROLLING HANDOVER, USER EQUIPMENT, BASE STATION, AND RADIO COMMUNICATION SYSTEM

SONY CORPORATION, Tokyo ...

1. A method for controlling a handover from a first base station to a second base station by a user equipment that performs radio communication over a communication channel formed by carrier aggregation of a plurality of component carriers, the method comprising:transmitting, from the first base station to the user equipment, scheduling information of each component carrier of the plurality of component carriers respectively according to a scheduling information transmission method that is a cross scheduling method;
commanding, by the first base station, the user equipment to perform the handover of the communication channel formed by carrier aggregation of the plurality of component carriers;
causing transfer of a first component carrier of the plurality of component carriers in the first base station to a first transferred component carrier in the second base station, the first component carrier being operated according to the cross scheduling method; and
stopping, by the first base station, transmission of the scheduling information of the first component carrier of the plurality of component carriers in the first base station.

US Pat. No. 10,368,279

COMMUNICATION METHOD, RADIO TERMINAL, AND BASE STATION

KYOCERA Corporation, Kyo...

1. A communication method comprising:transmitting first information for causing a radio terminal to hold context information of the radio terminal, from a network to the radio terminal in a radio resource control (RRC) connected state, wherein the context information includes a cell-radio network temporary identifier (C-RNTI) allocated to the radio terminal; and
in the radio terminal:
holding the context information without discarding the context information, based on the first information, even if the radio terminal transitions from the RRC connected state;
performing a cell reselection after transitioning from the RRC connected state;
receiving, from a reselected cell, information for determining whether the context information is available in the reselected cell; and
only when the context information is available in the reselected cell, performing control to transmit, to the reselected cell, information for promoting use of the context information, wherein
the radio terminal includes, into message 3 in a random access procedure, predetermined information for promoting the use of the context information, and
the message 3 is transmitted from the radio terminal to the reselected cell.

US Pat. No. 10,368,257

COMMUNICATION CONTROL DEVICE, COMMUNICATION CONTROL METHOD, PROGRAM, AND COMMUNICATION CONTROL SYSTEM

SONY CORPORATION, Tokyo ...

1. A communication control device, comprising:processing circuitry configured to
determine a communication status of wireless communication of image information from an image shooting device, the communication status indicating when an obstacle is within a first area associated with a first communication path of a plurality of communication paths, based on an operating room image captured by an operating room camera showing a situation of an operating room, each of the communication paths being a different line of sight communication path,
acquire information on a surgical site image captured by the image shooting device for display control of the surgical site image, and
select a second communication path of the communication paths from the image shooting device based on the determined communication status indicating when the obstacle is within the first area associated with the first communication path.

US Pat. No. 10,368,239

METHOD AND APPARATUS FOR PROVIDING BROADCAST CHANNEL ENCRYPTION TO ENHANCE CELLULAR NETWORK SECURITY

1. A method for encrypting a broadcast message of a base station, the method comprising:detecting, by a processor of the base station, a communication impairment at the base station, wherein the communication impairment pertains to a communication between the base station and an endpoint device;
selecting, by the processor of the base station, in response to the detecting the communication impairment, an encryption key for the broadcast message;
encrypting, by the processor of the base station, the broadcast message using the encryption key to create an encrypted broadcast message;
transmitting, by the processor of the base station, an identifier of the encryption key;
transmitting, by the processor of the base station, the encrypted broadcast message over a control channel via a first resource block, wherein the broadcast message includes information identifying that the control channel is to be reassigned from the first resource block to a second resource block; and
reassigning, by the processor of the base station, the control channel of the base station from the first resource block to the second resource block.

US Pat. No. 10,368,229

COMMUNICATION APPARATUS AND COMMUNICATION CONTROL METHOD IN A COMMUNICATION SYSTEM

NEC Corporation, Tokyo (...

1. A communication apparatus deployed between a terminal and an external network, which includes at least one service providing server, wherein the communication apparatus functions as a proxy to provide a service from the at least one service providing server to the terminal through the communication apparatus, the communication apparatus comprising:a virtual machine that manages a state of communication with the terminal and terminates a session for providing the service between the virtual machine and the terminal, wherein the virtual machine includes session information on the session, wherein the session information includes the state of communication; and
a controller configured to perform migration of the virtual machine including the session information, which includes the state of communication, either from another source communication apparatus to the communication apparatus or from the communication apparatus to another target communication apparatus.

US Pat. No. 10,368,227

ACCESS POINT MANAGEMENT AND USAGE IN A NETWORK ENVIRONMENT

Time Warner Cable Enterpr...

1. A method of determining where to install wireless access points in a network, the method comprising:receiving, from a subscriber device, a request for an installation of a new wireless access point at a specified geographical location in the network, the request being one of multiple requests indicating to install the new wireless access point at the specified geographical location;
determining whether a number of the multiple requests to install the new wireless access point exceeds a predetermined threshold value;
in response to detecting that the number of multiple requests exceeds the predetermined threshold value, initiating the installation of the new wireless access point at the specified geographical location; and
the method further comprising: initiating the installation of the new wireless access point at the specified geographical location based at least in part in response to detecting presence of the subscriber device at the geographical location.

US Pat. No. 10,368,213

LOCATION-BASED OPEN SOCIAL NETWORKS

1. An apparatus having stored executable instructions, comprising:1) at least one computing system being operable to implement a social networking system, the social networking system implementing a plurality of social networks;
2) the plurality of social networks each accessible without registration requirements;
3) the social networking system arranged to select a given number of first social networks among the plurality of social networks after receiving a request from a user, the first social networks each having virtual reality or augmented reality content that has more viewers than virtual reality or augmented reality content provided at each of rest of the plurality of social networks; and
4) the social networking system arranged to send the user information about the first social networks.

US Pat. No. 10,368,165

METHOD FOR ELIMINATING MOTOR VEHICLE AND WATER CRAFT HORN EMC INTERFERENCE AND HORN

11. A method of eliminating electromagnetic interference of an electronic device in a motor vehicle or a water craft, comprising:coupling at least one capacitor of about 220-10000 ?F in parallel with input terminals of a power supply of the electronic device to eliminate outbound electrical interference caused by electromagnetic radiation, conduction, or coupling that is generated by the electronic device.

US Pat. No. 10,368,164

APPROACH FOR PARTIALLY PRESERVING MUSIC IN THE PRESENCE OF INTELLIGIBLE SPEECH

HARMAN INTERNATIONAL INDU...

1. An audio processing system, comprising:an input device that receives a first audio signal;
a voice activity detector that:
receives a first control signal from a voice separator;
determines that a signal of interest is present in the first audio signal based on the first control signal exceeding a ducker threshold; and
generates a second control signal in response to the first audio signal; and
a ratio-based attenuator that:
receives the second control signal from the voice activity detector,
determines whether a first signal level associated with the first audio signal exceeds a second signal level associated with a second audio signal received from an audio playback device, and
if the first signal level exceeds the second signal, then maintains an audio level of the second audio signal, or
if the first signal level does not exceed the second signal level difference, then causes the audio level of the second audio signal to be adjusted from a first value to a second value.

US Pat. No. 10,368,162

METHOD AND APPARATUS FOR RECREATING DIRECTIONAL CUES IN BEAMFORMED AUDIO

GOOGLE LLC, Mountain Vie...

1. A method for recreating directional cues in beamformed audio, the method comprising:receiving at least one first audio signal via a microphone array;
receiving at least one second audio signal via the microphone array;
receiving at least one third audio signal via at least one reference microphone;
transforming the at least one first audio signal, the at least one second audio signal and the at least one third audio signal to a frequency domain representation;
beamforming amplitude data of the at least one transformed first audio signal, the at least one transformed second audio signal and the at least one transformed third audio signal to generate a beamformed monophonic audio signal;
deriving phase offset information based on a frequency extracted during the transforming of the at least one third audio signal and the beamformed monophonic audio signal; and
generating a multi-channel audio signal with directional cues by applying the derived phase offset information to the beamformed monophonic audio signal.

US Pat. No. 10,368,161

AMPLIFIER AND ELECTRONIC DEVICE USING THE SAME

ACER INCORPORATED, New T...

1. An amplifier, comprising:a first speaker;
a second speaker;
a third speaker;
an acoustic box, wherein the first speaker, the second speaker and the third speaker are disposed on a continuous surface inside the acoustic box; and
three partitions disposed on the continuous surface, one of the partitions is interposed between the first speaker and the second speaker, another one of the partitions is interposed between the second speaker and the third speaker, and another one of the partitions is interposed between the third speaker and the first speaker;
wherein one end of each partition is connected to the continuous surface where the first speaker, the second speaker and the third speaker are disposed, and another end of the partition is separated from an opposite surface facing the continuous surface by a gap;
wherein three connection lines of the first speaker, the second speaker and the third speaker form a triangle, and the partitions are connected to form a Y-shaped structure.

US Pat. No. 10,368,160

SPEAKER BOX

AAC TECHNOLOGIES PTE. LTD...

1. A speaker box, comprising:a lower cover;
an upper cover engaging with the lower cover for forming an accommodating space;
a speaker accommodated in the accommodating space, and including a diaphragm with a dome attached to the diaphragm;
a front sound cavity formed by the diaphragm and the upper cover;
air adsorbent particles received in the front sound cavity for absorbing the high frequency harmonic and noises; wherein
the dome forms at least one recess communicating with the front sound cavity, and the air adsorbent particles are received in the recesses.

US Pat. No. 10,368,159

WATER RESISTANT LOUDSPEAKER

18. A water resistant loudspeaker comprising:a. a water-impermeable spider having a first water-impermeable attachment to a former;
b. a spider support supported by said basket, wherein said spider support has at least one vent;
c. a water impermeable diaphragm having a second water-impermeable attachment to said former;
d. an acoustic chamber housing enclosing a rear acoustic chamber attached and sealed to a basket of said water resistant loudspeaker behind said spider and having a size adapted to maintain speaker performance at low frequencies; and
e. wherein said first attachment is adjacent said second attachment.

US Pat. No. 10,368,157

ADJUSTABLE EARCUP IN CONTINUOUS HEADBAND-SPRING HEADPHONE SYSTEM

BOSE CORPORATION, Framin...

1. A headphone system comprising:a pair of earcups;
a continuous headband spring connecting the pair of earcups, the continuous headband spring having an internal slot with an opening along an inner surface thereof; and
an adjustment apparatus coupled with one of the pair of earcups and the continuous headband spring, the adjustment apparatus comprising:
a shoe coupled with the one of the pair of earcups and positioned in the internal slot;
a tongue coupled with the shoe and extending at least partially along the continuous headband spring; and
a resistance member coupled with the tongue for resisting movement of the tongue relative to the continuous headband spring, wherein the resistance member comprises a friction box, and wherein the friction box comprises:
a housing coupled to the continuous headband spring; and
at least a set of damping pads for engaging the tongue as the tongue moves relative to the continuous headband spring.

US Pat. No. 10,368,156

CONFIGURABLE EARBUD RETENTION AND STABILIZATION SYSTEM

1. A configurable earbud retention and stabilization system, comprising:a bendable earloop configured to fit over an ear of a user, the bendable earloop having a first end and a second end oppositely disposed relative to the first end, the bendable earloop defining a clip aperture proximate to the first end, the bendable earloop configured to be deformed into a plurality of different positions so as to provide a customized fit for the user; and
an earbud clip, the earbud clip forming a cavity configured to receive an earbud headphone therein, the earbud clip including a connecting member received within the clip aperture of the bendable earloop so as to detachably couple the earbud clip to the bendable earloop, the connecting member of the earbud clip comprising a shaft portion and a cap portion, the shaft portion of the earbud clip received within the clip aperture of the bendable earloop, and the cap portion of the earbud clip retaining the earbud clip in engagement with the bendable earloop while restricting the earbud clip to rotation about a single rotational axis which extends longitudinally through the connector member.